Page last updated: 2024-12-06

stavudine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Stavudine, also known as d4T, is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV/AIDS. It is a synthetic analog of deoxycytidine that acts by inhibiting the activity of HIV reverse transcriptase, the enzyme that converts the virus's RNA into DNA. Stavudine is typically used in combination with other antiretroviral drugs. It is available in oral tablet form. Stavudine has been associated with side effects including peripheral neuropathy, lactic acidosis, and lipodystrophy. It is no longer recommended for first-line treatment of HIV due to concerns about its toxicity and the availability of more effective and safer alternative medications. However, it is still used in some cases, particularly in resource-limited settings.'

Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18283
CHEMBL ID991
CHEBI ID63581
SCHEMBL ID38661
MeSH IDM0027323

Synonyms (183)

Synonym
BIDD:GT0082
MLS001077292
MLS000028546 ,
bmy-27857
zerit
EU-0100336
2',3'-didehydro-3'-deoxythymidine, >=98% (tlc)
3'- azido-3'-deoxythymidine & granulocyte-macrophage colony-stimulating factor
thymidine, 2',3'-didehydro-, 3'-deoxy-
zerit(tm)
bmy 27857
ddetyd
d4tmby-27857-3
STV ,
1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1h,3h)-pyrimidinedione & colony-stimulating factor 2
d4t & gm-csf
ddethd
NCGC00023212-04
2',3'-didehydro-3'-deoxythymidine ,
NCGC00023212-03
dideoxydidehydrothymidine
smr000673569
MLS001055348
nsc 163661
estavudina [inn-spanish]
zerut xr
hsdb 7338
brn 0618327
2'-thymidinene, 3'-deoxy-
3'-deoxy-2',3'-didehydrothymidine
thymidine, 2',3'-didehydro-3'-deoxy-
d 4t (nucleoside)
d 4t
stavudinum [inn-latin]
2',3'-didehydro-3'-deoxythimidine
C07312
3056-17-5
sanilvudine
stavudine
d4t ,
nsc-163661
3'-deoxy-2'-thymidinene
nsc163661
MLS000759504
1-(2,3-dideoxy-beta-d-glycero-pent-2-enofuranosyl)thymine
NCGC00023212-07
DB00649
D00445
zerit (tn)
sanilvudine (jan)
stavudine (usan/inn)
NCGC00023212-09
smr000058350
LOPAC0_000336
1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1h,3h)-dione
NCGC00023212-05
NCGC00023212-08
bmy27857
2',3' didehydro 3' deoxythymidine
2',3'-didehydro-2',3'-dideoxythmidine
D 1413 ,
HMS2051O20
2',3'-anhydrothymidine; d4t
AC-5263
1-(2,3-dideoxy-beta-d-glycero-2-pentenofuranosyl)thymine
D3580
NCGC00023212-10
stavudine (dt4)
chebi:63581 ,
CHEMBL991 ,
stavudine (d4t)
d-4t
stavudinum
nsc-759897
1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
STK801888
cid_18283
3''-deoxy-2'',3''-didehydrothymidine
1-((2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
2'',3''-didehydro-3''-deoxythymidine
bdbm50013111
3''-deoxy-2''-thymidine
1-(5-hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1h-pyrimidine-2,4-dione (ddethd)
2'',3''-dideoxy-2'',3''-didehydrothymidine
1-((2r,5s)-5-hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1h-pyrimidine-2,4-dione
1-(5-hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1h-pyrimidine-2,4-dione
cid_5155
zerit xr
AKOS005622554
NCGC00023212-11
NCGC00023212-12
NCGC00023212-13
HMS3259L21
HMS3261C13
HMS3039O05
estavudina
bo9le4qfzf ,
stavudine [usan:usp:inn:ban]
thymine, 1-(2,3-dideoxy-beta-d-glycero-pent-2-enofuranosyl)-
unii-bo9le4qfzf
NCGC00258944-01
tox21_300583
NCGC00254372-01
tox21_201393
MLS001424091
pharmakon1600-01502339
nsc759897
dtxcid803819
tox21_110886
cas-3056-17-5
dtxsid1023819 ,
HMS2234C10
CCG-100902
stavudine [usan:ban:inn]
LP00336
1-(2,3-dideoxy-.beta.-d-glycero-pent-2-enofuranosyl)thymine
stavudine [who-dd]
stavudine [mi]
stavudine [hsdb]
stavudine (d4t) [vandf]
stavudine [ep impurity]
stavudine [mart.]
stavudine [who-ip]
stavudine [orange book]
zidovudine impurity a [who-ip]
stavudine (dt4) [vandf]
stavudine [ep monograph]
sanilvudine [jan]
stavudinum [who-ip latin]
stavudine [ema epar]
stavudine [usan]
stavudine [usp monograph]
zidovudine impurity a [ep impurity]
stavudine [usp-rs]
stavudine [inn]
BBL033763
CS-1872
HY-B0116
NC00684
NC00152
1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SCHEMBL38661
NCGC00023212-14
tox21_110886_1
KS-1115
tox21_500336
J-700246
NCGC00261021-01
MLS006011922
Q-201742
1-[(2r,5s)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-2,4(1h,3h)-pyrimidinedione
HMS3428C07
AB00383018_18
OPERA_ID_1281
3'-deoxythymidin-2'-ene
1-(2,3-dideoxy-beta-glycero-pent-2-enofuranosyl)thymine
stavudine, united states pharmacopeia (usp) reference standard
stavudine, european pharmacopoeia (ep) reference standard
stavudine for system suitability, european pharmacopoeia (ep) reference standard
SR-01000075802-4
sr-01000075802
SR-01000075802-1
HMS3714N22
Q423984
gtpl12678
BD164571
BCP02952
EN300-120634
SDCCGSBI-0050324.P002
NCGC00023212-25
220020-60-0
1-(cis-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
stavudine 100 microg/ml in acetonitrile
NCGC00023212-30
stavudine- bio-x
stavudin
didehydrodeoxythymidine
stavudine (usp-rs)
stavudine (mart.)
stavudine (usp monograph)
stavudine (ep monograph)
Z1530425068

Research Excerpts

Overview

Stavudine is an anti-AIDS drug widely used to prevent HIV transmission from pregnant mothers to the fetuses in underdeveloped countries for its low price. It is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries.

ExcerptReferenceRelevance
"Stavudine is an anti-AIDS drug widely used to prevent HIV transmission from pregnant mothers to the fetuses in underdeveloped countries for its low price. "( Stavudine exposure results in developmental abnormalities by causing DNA damage, inhibiting cell proliferation and inducing apoptosis in mouse embryos.
Ao, RF; Liang, YX; Liu, D; Liu, XQ; Sun, G; Tan, K; Wang, X; Xie, J; Zhang, T, 2020
)
3.44
"Stavudine is an antiretroviral therapy with so many side effects and has a short half-life of 1.5 h. "( Application of SRMS 154 as Sustained Release Matrix for the Delivery of Stavudine:
Attama, AA; Chime, SA; Onunkwo, GC, 2020
)
2.23
"Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries. "( Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
Ait-Mohand, H; Amellal, B; Behin, A; Bennai, Y; Bonmarchand, M; Calvez, V; Guiguet, M; Katlama, C; Marguet, F; Murphy, R; Peytavin, G; Pialoux, G; Slama, L, 2008
)
2.02
"Stavudine is a nucleoside reverse transcriptase inhibitor active against HIV, and is known to exist in two polymorphic forms designated as forms I and II, and a hydrate form III. "( The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine.
de Villiers, M; Liebenberg, W; Strydom, S; Yu, L, 2009
)
2.02
"Stavudine is an effective and inexpensive antiretroviral drug, but no longer recommended by WHO for first-line antiretroviral regimens in resource-limited settings due to toxicity concerns. "( Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi.
Chagoma, N; Heyderman, RS; Kampira, E; Kaunda, S; Mallewa, J; Mukaka, M; Njalale, Y; van Oosterhout, JJ, 2012
)
3.26
"Stavudine is a commonly used drug in paediatric antiretroviral treatment (ART) regimens. "( Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M, 2013
)
2.2
"Stavudine is a potent nucleoside analogue and a well-recognized component of highly active antiretroviral therapy. "( The reassurance of experience.
Martínez, E, 2003
)
1.76
"Stavudine use is a contributing factor for lipoatrophy, whereas use of abacavir or zidovudine is less likely to cause this complication. "( Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
Fisher, RL; Hernandez, JE; Hessenthaler, SM; Lonergan, JT; McComsey, GA; Sension, MG; Shalit, P; Ward, DJ; Williams, VC, 2004
)
1.97
"Stavudine is an inhibitor of HIV reverse transcriptase and acts as a chain terminator during DNA synthesis. "( Stavudine effects on rat pregnancy outcome.
Amed, AM; Barreto, RL; de Jesus Simões, M; Kulay, L; Oliveira-Filho, RM; Soares Júnior, JM, 2004
)
3.21
"Stavudine (d4T) is a nucleoside analogue approved for the treatment of HIV infection. "( Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity.
Barreiro, P; de Mendoza, C; Gonzalez-Lahoz, J; Jiménez-Nacher, I; Sánchez-Conde, M; Soriano, V,
)
1.93
"Stavudine is a nucleoside analogue used for the treatment of HIV-1 infection, as part of highly active antiretroviral treatment. "( Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
Gatell, J; Hanvanich, M; Hill, A; Katlama, C; Milinkovic, A; Ribera, E; Ruxrungtham, K; Soriano, V; Wolf, E, 2007
)
2.02
"Stavudine is a hepatotoxic antiretroviral nucleoside analogue that also inhibits the replication of mitochondrial DNA (mtDNA). "( Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.
Lebrecht, D; Setzer, B; Walker, UA, 2008
)
2
"Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. "( Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.
Faulds, D; Lea, AP, 1996
)
3.18
"Stavudine is a promising antiretroviral agent, but its clinical efficacy has not been determined."( Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
Cross, A; Dellamonica, P; Dunkle, L; Gathe, J; Jemsek, JG; Mellors, JW; Murphy, R; Pavia, AT; Spruance, SL; Stool, E, 1997
)
2.01
"Stavudine is an important agent to consider for trials of combination chemotherapy."( Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
Cross, A; Dellamonica, P; Dunkle, L; Gathe, J; Jemsek, JG; Mellors, JW; Murphy, R; Pavia, AT; Spruance, SL; Stool, E, 1997
)
1.29
"Stavudine (d4T) is a pyrimidine nucleoside analogue used in the treatment of human immunodeficiency virus (HIV) infection. "( Clinical pharmacokinetics of stavudine.
Dudley, MN; Rana, KZ, 1997
)
2.03
"Stavudine is a thymidine nucleoside analogue which is phosphorylated intracellularly to an active metabolite, stavudine 5'-triphosphate. "( Stavudine: an update of its use in the treatment of HIV infection.
Hurst, M; Noble, S, 1999
)
3.19
"Stavudine (d4T) is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. "( Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line.
Antonelli, G; Dianzani, F; Simeoni, E; Turriziani, O, 1998
)
2.03
"Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic index in a range of T lymphocyte and haematopoietic precursor cell lines."( The role of stavudine in the management of adults with HIV infection.
Gazzard, BG; Moyle, GJ, 1997
)
1.4
"Stavudine is a new dideoxynucleoside with more complete and less variable oral absorption than existing nucleosides used for treatment of human immunodeficiency virus infection."( Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.
Browne, M; Dudley, MN; Dunkle, L; Geletko, S; Graham, KK; Kaul, S; Mayer, K, 1992
)
1.33

Effects

Stavudine (d4T) has been associated with lipoatrophy and hyperlactatemia. It has shown a favourable short and long-term tolerability profile.

ExcerptReferenceRelevance
"Stavudine has a low incidence of clinically significant adverse events, and those experienced are generally long-term, manageable class effects."( The reassurance of experience.
Martínez, E, 2003
)
1.04
"Stavudine has a low incidence of clinically significant adverse events, and those experienced are generally long-term, manageable class effects."( The reassurance of experience.
Martínez, E, 2003
)
1.04
"Stavudine (d4T) has been observed in clinical trials and cohort studies to be more often implicated in cases of hyperlactatemia than other nucleoside reverse transcriptase inhibitors, possibly because of its relatively greater propensity to induce mitochondrial toxicity. "( Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
File, TM; Fisher, RL; Hernandez, JE; Hessenthaler, SM; Lindsey, L; Lonergan, JT; McComsey, GA; Shalit, P; Ward, DJ; Williams, VC, 2004
)
2
"Stavudine (d4T) has been associated with lipoatrophy and hyperlactatemia. "( Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study.
Alcolea, A; Blanco, F; Cruz, JJ; García-Benayas, T; González-Lahoz, J; Soriano, V, 2004
)
1.99
"Stavudine (d4T) has shown a favourable short and long-term tolerability profile. "( [Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions].
Arazo, P; Cartón, JA; Deig, E; del Pozo, MA; Flores, J; Jusdado, JJ; Martín, T; Pedrol, E; Ribera, E; Sanz, J, 2007
)
2.05
"Stavudine has been shown to be less myelosuppressive than zidovudine."( Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues.
Sommadossi, JP, 1995
)
1.25
"Stavudine has also been beneficial as part of combination regimens in antiretroviral-experienced patients and children with HIV infection, although data are limited and more studies are needed."( Stavudine: an update of its use in the treatment of HIV infection.
Hurst, M; Noble, S, 1999
)
2.47

Actions

ExcerptReferenceRelevance
"Stavudine use increase the risk of macrocytosis more than 40-fold in HIV-infected patients who do not receive zidovudine. "( Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study.
Anwar, D; Geené, D; Goehring, C; Hirschel, B; Saaïdia, A; Sudre, P, 2000
)
1.75

Treatment

Stavudine-treated groups have experienced significant increases in mean CD4 cell counts and decreases in both mean serum p24 antigen levels and infectious HIV titers in peripheral blood mononuclear cells. StavUDine-based treatment regimens in low-income countries are associated with significant long-term toxicities.

ExcerptReferenceRelevance
"Stavudine-based treatment regimens in low-income countries are associated with significant long-term toxicities, predominantly lipoatrophy. "( Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.
Choun, K; Lynen, L; Phan, V; Thai, S; van Griensven, J, 2012
)
2.08
"Stavudine treatment compared with zidovudine resulted in a greater percentage of patients with AIDS-defining events (14.5 vs."( Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
Becker, SL; Danehower, SC; Fusco, GP; Fusco, JS; Graham, NM; Hansen, NI; Justice, AC; Sherrill, BH; Stein, DS, 2004
)
1.29
"Stavudine-treated groups have experienced significant increases in mean CD4 cell counts and decreases in both mean serum p24 antigen levels and infectious HIV titers in peripheral blood mononuclear cells."( Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).
Anderson, RE; Mellors, JW; Riddler, SA, 1995
)
1.31

Toxicity

Lipoatrophy is the most stigmatizing side effect of stavudine therapy. Patients in the stavUDine group had a greater probability of an adverse event that led to study drug discontinuation through week 60 than those in the emtricitabine group.

ExcerptReferenceRelevance
" CBV was only moderately toxic to human and murine cells following either 1 h or continuous exposure, with human and murine progenitors similarly suppressed by continuous CBV exposure."( In vitro toxicity of 3'-azido-3'-deoxythymidine, carbovir and 2',3'-didehydro-2',3'-dideoxythymidine to human and murine haematopoietic progenitor cells.
Du, DL; Grieshaber, CK; Murphy, MJ; Volpe, DA, 1992
)
0.28
" Combination therapy was well tolerated, and there were no drug-associated clinical or laboratory adverse events."( Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
Dunkle, LM; Evans, KD; Federici, ME; Fletcher, CV; Harris, AT; Kline, MW; Rutkiewicz, VL; Shearer, WT, 1996
)
0.6
"Combination therapy with stavudine and didanosine was well tolerated and safe in this small group of children with advanced HIV disease."( Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
Dunkle, LM; Evans, KD; Federici, ME; Fletcher, CV; Harris, AT; Kline, MW; Rutkiewicz, VL; Shearer, WT, 1996
)
0.9
"Combination therapy with stavudine and didanosine is safe and leads to a sustained antiviral effect, even in patients with prolonged prior antiretroviral exposure and low CD4+ cell counts."( Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.
Auger, S; Besnier, JM; Billaud, E; Billaudel, S; Chennebault, JM; Lafeuillade, A; May, T; Michelet, C; Perre, P; Raffi, F; Reliquet, V, 1998
)
0.91
" Dosages were adjusted appropriately for patients weighing <60 kg and reduced in response to adverse effects."( Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.
Beall, G; Cross, AP; Dunkle, LM; Gathe, J; Hardy, D; Murphy, RL; Peterson, D; Pollard, RB; Pottage, J; Reynolds, L; Rutkievicz, V, 1999
)
0.54
" Although 95% of patients reported an adverse event of grade 1 or higher, only 1 patient experienced a grade 3 or 4 adverse event (maculopapular rash) related to nelfinavir."( The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Adler, M; Cross, AP; Dunkle, LM; Elion, R; Kaul, S; Kelleher, T; Knupp, C, 1999
)
0.54
"7%) patients because of adverse events and three (3."( Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W, 2000
)
0.31
"Our preliminary data suggest that the protease inhibitor combination ritonavir/indinavir plus double nucleoside therapy appears to be effective and safe in short-term treatment (up to 24 weeks)."( Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W, 2000
)
0.31
" The association of adherence with demographic variables, hepatitis C virus infection, number of stopped antiretroviral regimens, HIV RNA level, CD4 cell count, and adverse effects to drugs was assessed."( Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Arnedo, A; Gómez, CJ; Roca, B, 2000
)
0.57
" In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding."( Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.
Danner, SA; Dreezen, C; Gisolf, EH; Weel, JL; Weverling, GJ, 2000
)
0.52
"A 6-month study of 8 children with advanced HIV infection shows that combination therapy with d4T and ddI is safe and well tolerated."( Drug combo safe for HIV-infected children.
, 1996
)
0.29
"Treatment with a dual combination of didanosine plus stavudine in naive children with nonadvanced HIV disease is safe and provides a satisfactory virological outcome at 1 year."( Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
Asensi, F; Ciria, L; de José, MI; de Mendoza, C; Fortuny, C; García, FJ; Ramos, JT; Soriano, V,
)
0.69
" No serious adverse events were observed."( Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Boonrod, C; Chuenyam, T; Cooper, DA; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P; Ubolyam, S; van Heeswijk, RP, 2002
)
0.31
" No significant differences were detected between the treatment groups in virological or immunological response or cessation of study drugs due to adverse events, although it is possible that the study was underpowered to detect differences."( Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
Amin, J; Carr, A; Cooper, D; Drummond, F; Emery, S; French, M; Law, M; Roth, N,
)
0.13
"The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended."( Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C, 2003
)
0.53
"This data supports the strategy that in cases of symptomatic hyperlactatemia or lactic acidosis in which the toxicity is associated with stavudine, didanosine or both, it is safe and efficacious to reintroduce NRTI that are less potent inhibitors of mitochondria."( Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Barber, RE; Lonergan, JT; Mathews, WC, 2003
)
0.52
" The first group (A) consisted of patients with presumed NRTI-related adverse events (n=21), the second group (B) consisted of patients without adverse events (n=28), the third group (C) were HIV-infected patients without antiretroviral therapy (n=6) and the last group (D) were healthy controls (n=12)."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
" All patients with lactate values above 2700 micromol/l (eight) experienced adverse events."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
"Lactate levels were higher in patients with presumed NRTI-related adverse events."( Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004
)
0.32
" Ten patients discontinued the study treatment before W48: adverse events (eight), patient's will (one) and simplification of therapy (one)."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
"IDV/RTV 400/100 mg twice daily is an effective and safe first-line antiretroviral therapy."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
" Twenty-eight patients discontinued therapy prior to week 204 because of adverse events (n = 10), lost to follow-up (n = 9), or other reasons (n = 9)."( Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Benson, C; Brun, SC; Eron, JJ; Gulick, RM; Hicks, C; Kessler, HA; King, KR; King, MS; Murphy, RL; White, AC, 2004
)
0.32
"An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus and chronic hepatitis C virus who were treated with a regimen of ribavirin and didanosine, with or without stavudine, were at increased risk for events associated with mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis."( Nucleoside analogues and mitochondrial toxicity.
Boxwell, D; Fleischer, R; Sherman, KE, 2004
)
0.5
" No new safety issues were identified, and the overall incidence of treatment-emergent adverse events during BMS AI424-044 was comparable across treatment groups."( Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Cahn, P; Giordano, M; Kelleher, T; Mancini, M; Murphy, R; Pantaleo, G; Phanuphak, P; Pokrovskiy, V; Rozenbaum, W; Sension, M; Wood, R, 2004
)
0.58
"5), severe adverse effects 17."( Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Andrieux-Meyer, I; Bourgeois, A; Calmy, A; Delaporte, E; Kazatchkine, M; Kouanfack, C; Koulla-Shiro, S; Lactuock, B; Laurent, C; Liégeois, F; Mougnutou, R; Mpoudi-Ngolé, E; Nerrienet, E; Nkoué, N; Nzeusseu, V; Peeters, M; Peytavin, G; Tardy, M; Zekeng, L,
)
0.36
" In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60% patients with viremia<400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p=0."( Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005
)
0.33
" Several observational studies have described a higher frequency of antiretroviral-related adverse effects among women compared with men."( Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Clark, R, 2005
)
0.33
" Treatment was stopped in 18 patients; two from intolerance, two switched therapy, four as a result of serious adverse event-related death, and ten were lost to follow-up."( Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P, 2005
)
0.33
"Our study demonstrates that indinavir/ritonavir 400/100 mg plus stavudine and lamivudine twice daily, the least expensive boosted protease inhibitor, appears to be effective and safe up to 96 weeks despite high baseline viraemia and low CD4+ cell count in antiretroviral-naive patients."( Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P, 2005
)
0.57
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Decrease in viral load of HIV (VC) has been assessed as primary endpoint and as secondary one, the increase of the numbers of CD4 lymphocytes, percentage of disease progression, adverse reactions and adherence."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
" Treatment was discontinued due to adverse reactions: 24% in regimen 1, 48% in regimen 2, 26% in regimen 3 and 32% in regimen 4, without significant difference."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
"In the HIV positive patients with advanced infection, efficacy between the four regimens of HAART is similar, but there is a tendency to require more withdrawal due to adverse effects in the RTV group than in those of IDV, the two used as single PI."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
" No STAMP-related toxic lesions were found in any of the organs from STAMP-treated cats or dogs."( In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats.
Erbeck, D; Tibbles, H; Uckun, FM; Venkatachalam, TK; Waurzyniak, B, 2006
)
0.33
" However, few nonclinical studies have examined the potential for adverse drug interactions."( Prenatal developmental toxicity evaluation of 2',3'-dideoxyinosine (ddI) and 2',3'-didehydro-3'-deoxythymidine (d4T) co-administered to Swiss Albino (CD-1) mice.
Bieler, GS; George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ; Williams, RL, 2006
)
0.33
"In pregnant mice, ddI/d4T combinations were not associated with well-defined developmental toxicity or adverse drug interactions."( Prenatal developmental toxicity evaluation of 2',3'-dideoxyinosine (ddI) and 2',3'-didehydro-3'-deoxythymidine (d4T) co-administered to Swiss Albino (CD-1) mice.
Bieler, GS; George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ; Williams, RL, 2006
)
0.33
"Retrospective chart review of experienced patients on ddI plus d4T was conducted at a single institution, recording the development of adverse events as well as their severity and action taken."( Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients.
Antela, A; Casado, JL; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ, 2006
)
0.56
" Adverse events related to ddI plus d4T were recorded in 136 patients (22."( Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients.
Antela, A; Casado, JL; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ, 2006
)
0.56
" Adverse event-related discontinuations were 8% among ATV300/RTV-treated patients and <1% among ATV400-treated patients."( Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
David, N; Hammond, J; Krantz, E; Malan, DR; McGrath, D; Wirtz, V, 2008
)
0.35
"Changing from drugs that have significant mitochondrial toxicity to less toxic compounds may be of benefit in human immunodeficiency virus (HIV)-positive patients who receive highly active antiretroviral therapy."( Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Cossarizza, A; Dentone, C; Di Biagio, A; Esposito, R; Ferraresi, R; Mussini, C; Nasi, M; Nemes, E; Pinti, M; Repetto, E; Rosso, R; Viscoli, C, 2008
)
0.64
" These adverse effects were completely abrogated by uridine."( Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.
Lebrecht, D; Setzer, B; Walker, UA, 2008
)
0.55
"To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India."( Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
Balakrishnan, P; Cecelia, AJ; Devaleenal, B; Flanigan, TP; Kumarasamy, N; Lai, AR; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2008
)
0.35
"To review the toxic effects of stavudine and their prevention and management strategies, especially in resource-limited settings."( Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings.
Delaporte, E; Kouanfack, C; Laurent, C; Makinson, A; Moing, VL, 2008
)
1.03
"Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries."( Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
Ait-Mohand, H; Amellal, B; Behin, A; Bennai, Y; Bonmarchand, M; Calvez, V; Guiguet, M; Katlama, C; Marguet, F; Murphy, R; Peytavin, G; Pialoux, G; Slama, L, 2008
)
2.02
"In two randomized, controlled trials, small differences in glomerular filtration rate over time were noted but no clinically relevant renal disease or adverse events were demonstrated in antiretroviral-naive patients treated with TDF through 144 weeks."( The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Chen, SS; Cheng, AK; DeJesus, E; Enejosa, JV; Gallant, JE; Pozniak, AL; Winston, JA, 2008
)
0.35
" Twenty-five patients (62%) experienced at least one adverse event."( Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.
Bates, M; Castelnuovo, B; Colebunders, R; John, L; Kamya, MR; Lutwama, F; Ronald, A; Spacek, LA,
)
0.13
"The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy."( [Tenofovir as a strategy to avoid or limit adverse effects].
Portilla, J, 2008
)
0.35
"Lipoatrophy is the most stigmatizing side effect of stavudine therapy."( Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Castella, E; Crespo, M; Curran, A; Del Saz, SV; Diaz, M; Falcó, V; Feijoo, M; García-Arumí, E; Ocaña, I; Pahissa, A; Paradiñeiro, JC; Planas, M; Puiggròs, C; Ribera, E; Sauleda, S; Sureda, D,
)
0.59
"To describe the safe substitution with zidovudine (AZT) among South Indian HIV-infected patients who were initiated with stavudine (d4T)-containing highly active antiretroviral therapy (HAART) due to anemia."( Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
Ambrose, P; Devaleenol, B; Kumarasamy, N; Manohar, D; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2009
)
0.79
" In settings where tenofovir is either expensive or not available and where patients are anemic, initiating d4T followed by prompt substitution with AZT can be a safe and tolerable treatment option."( Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
Ambrose, P; Devaleenol, B; Kumarasamy, N; Manohar, D; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2009
)
0.58
"In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative."( Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?
Castelnuovo, B; Kamya, M; Nanyonjo, A; Ocama, P, 2008
)
0.87
" Grade 3-4 adverse events occurred in 3 cases (2 peripheral neuropathy, and 1 suspected lactic acidosis)."( [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009
)
0.35
"Antiretroviral therapy with NVP-based regimens is safe and effective by suppressing HIV viremia and producing continued CD4 cell increases in subjects with HIV or AIDS for 6 years."( [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009
)
0.35
"This review highlights the toxic and genotoxic effects of NRTIs, particularly lamivudine (3TC) and stavudine (d4T) analogues."( The genetic toxicity effects of lamivudine and stavudine antiretroviral agents.
Cunha, KS; de Andrade, HH; Dihl, RR; Guimarães, NN; Lehmann, M, 2010
)
0.83
"Considering that AIDS has become a chronic disease, more comprehensive toxic genetic studies are needed, with particular attention to the genetic alterations induced by NRTIs."( The genetic toxicity effects of lamivudine and stavudine antiretroviral agents.
Cunha, KS; de Andrade, HH; Dihl, RR; Guimarães, NN; Lehmann, M, 2010
)
0.62
"The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children."( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010
)
0.61
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The main early side effect was peripheral neuropathy (7."( Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.
Choun, K; Lynen, L; Phan, V; Thai, S; van Griensven, J, 2012
)
0.64
"Lower stavudine dosage is associated with fewer reports of several stavudine-associated adverse events and also a lower risk of stavudine discontinuation within the first year on ART."( Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.
Fox, MP; Maotoe, T; Maskew, M; Sanne, IM; Westreich, D, 2012
)
1.12
"Assessment of the mitochondrial/nuclear DNA ratio by qPCR performed better than the mitochondrial/nuclear-encoded protein ratio by flow cytometry to detect adverse effects of nucleoside analogs on mitochondria."( Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry.
Côté, HC; Frenkel, LM; Jerome, KR; Lin, CH; Sloan, DD; Tobin, NH; Wagner, TA,
)
0.13
" Lipodystrophy accounted for 87 of 96 toxic events."( Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M, 2013
)
0.76
" Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes."( Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011
)
0.37
" No subjects discontinued study drug because of an adverse event in the 48 weeks of randomized phase."( A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K, 2015
)
0.65
" We also found no significant differences between the two groups for adverse events and death."( Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
Adetokunboh, OO; Balogun, TA; Schoonees, A; Wiysonge, CS, 2015
)
0.42
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
"Our findings suggest that ART drugs are not associated with an increased risk of CMs, yet some may increase adverse birth events."( Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018
)
0.48
" Adverse events assessments included measures of bone density and body fat."( Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Akpomiemie, G; Arulappan, N; Becker, S; Chersich, MF; Duncombe, C; Feldman, C; Hill, A; Kambugu, A; Kumarasamy, N; Majam, M; Moorhouse, M; Poongulali, S; Ripin, DHB; Sokhela, S; Venter, WDF; Vos, A, 2019
)
0.75
" Drug-related adverse event discontinuations were higher with d4T (6."( Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Akpomiemie, G; Arulappan, N; Becker, S; Chersich, MF; Duncombe, C; Feldman, C; Hill, A; Kambugu, A; Kumarasamy, N; Majam, M; Moorhouse, M; Poongulali, S; Ripin, DHB; Sokhela, S; Venter, WDF; Vos, A, 2019
)
0.75

Pharmacokinetics

The dNN study evaluated the safety, efficacy and pharmacokinetic interactions of the combination of stavudine, nelfinavir and nevirapine in 25 HIV-infected subjects. The method was successfully applied to quantify them in a rat Pharmacokinetic study in whole blood, plasma and DBS cards after a single oral co-administration.

ExcerptReferenceRelevance
"67, or 4 mg/kg of body weight; 17 of them underwent an additional steady-state pharmacokinetic evaluation after thrice-daily dosing of the above doses."( Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.
Browne, M; Dudley, MN; Dunkle, L; Geletko, S; Graham, KK; Kaul, S; Mayer, K, 1992
)
0.61
" The pharmacokinetic properties of these compounds in rhesus monkeys after intravenous, oral, and subcutaneous administration of the drug were compared."( Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.
Boudinot, FD; Doshi, KJ; McClure, HM; Schinazi, RF, 1990
)
0.28
"More than 7 years after the introduction of zidovudine for treatment of HIV infection, little use has been made of the pharmacokinetic properties of this or any of the subsequently approved antiretroviral agents to optimise therapy."( Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Stretcher, BN, 1995
)
0.29
" The published pharmacokinetic data for the nucleoside antiretroviral agents zidovudine, didanosine, zalcitabine, stavudine, and lamivudine show that administration of fixed doses of certain agents results in a considerable degree of between-patient variability in in vivo drug exposure."( Clinical pharmacokinetics of nucleoside antiretroviral agents.
Dudley, MN, 1995
)
0.5
" The ability of this in vitro pharmacodynamic model to assess the response of HIV-infected cells to different doses and schedules of antiviral agents may be useful in the design of optimal dosing regimens for clinical trials but requires validation with other types of antiretroviral agents."( Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.
Bauer, G; Bilello, JA; Cole, GA; Drusano, GL; Dudley, MN, 1994
)
0.29
" Plasma and urine samples were analyzed for stavudine by high-performance liquid chromatography, and pharmacokinetic parameters were derived by a noncompartmental method."( Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.
Dandekar, KA; Kaul, S, 1993
)
0.78
" Each patient underwent inpatient pharmacokinetic studies following administration of the first oral stavudine dose; 59 patients were restudied after chronic therapy for an average of 19 days."( Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.
Anderson, R; Dudley, MN; Dunkle, L; Horton, CM; Kaul, S; Mayer, KH; Squires, K, 1995
)
0.79
"To obtain preliminary information on the pharmacokinetic properties, tolerance, safety, and antiviral activity of combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus (HIV) infection."( Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
Dunkle, LM; Evans, KD; Federici, ME; Fletcher, CV; Harris, AT; Kline, MW; Rutkiewicz, VL; Shearer, WT, 1996
)
0.8
"Analysis of stavudine and didanosine plasma half-life values, clearances, and area under the plasma concentration-versus-time curves revealed no obvious clinical pharmacokinetic interaction between the drugs through study week 12."( Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
Dunkle, LM; Evans, KD; Federici, ME; Fletcher, CV; Harris, AT; Kline, MW; Rutkiewicz, VL; Shearer, WT, 1996
)
0.98
" The pharmacokinetic properties of stavudine in children are similar to those of adults."( Clinical pharmacokinetics of stavudine.
Dudley, MN; Rana, KZ, 1997
)
0.87
" In the presence of zalcitabine, the only statistically significant change in the pharmacokinetic parameters of ganciclovir was a 22."( The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
AbdelHameed, MH; Dorr, A; Griffy, K; Jung, D; Teitelbaum, P, 1999
)
0.53
"The indinavir dosage regimen currently used for human immunodeficiency virus (HIV)-infected children is not based on pharmacokinetic data obtained in the target patient population."( Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Bassetti, D; Bassetti, M; Gatti, G; Principi, N; Sala, N; Vella, S; Vigano', A, 2000
)
0.31
" In this study we analysed the pharmacokinetic profile of nelfinavir after multiple oral doses in 18 HIV-infected patients during a combination regimen of nelfinavir plus efavirenz and stavudine."( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000
)
0.73
"The dNN study evaluated the safety, efficacy and pharmacokinetic interactions of the combination of stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T), nelfinavir and nevirapine in 25 HIV-infected subjects who received treatment for up to 29 weeks."( dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron, G, 1998
)
0.91
" The bioanalytical assay has been used in a pharmacokinetic study of pregnant women and their newborns."( Determination of stavudine in human plasma and urine by high-performance liquid chromatography using a reduced sample volume.
Carné, X; Riba, N; Sarasa, M; Zamora, L, 2000
)
0.65
"We sought to examine variation in pharmacokinetic parameters of stavudine in Japanese patients infected with HIV-1."( Determination of pharmacokinetic parameters of stavudine in Japanese patients infected with HIV-1, using a Gaussian-like input rate function.
Ito, A; Kawata, K; Kuwabara, R; Tatsunami, S; Yamada, K,
)
0.63
" Pharmacokinetic evaluations were performed at 14 and 28 days of age."( Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Boonrod, C; Chuenyam, T; Cooper, DA; Damle, BD; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P, 2001
)
0.63
" Intensive pharmacokinetic evaluations were performed at 14 and 28 days of age."( Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Boonrod, C; Chuenyam, T; Cooper, DA; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P; Ubolyam, S; van Heeswijk, RP, 2002
)
0.31
" Median values of the primary pharmacokinetic parameters of nelfinavir 30 mg/kg every-8-hours (n = 8) and 45 mg/kg every 12 hours (n = 10) were, respectively, for the area under the plasma concentration-time curve over 24 hours, 90."( The pharmacokinetics of nelfinavir in HIV-1-infected children.
Beijnen, JH; de Koning, LA; Heymans, HS; Hoetelmans, RM; Lange, JM; Scherpbier, HJ; van Heeswijk, RP, 2002
)
0.31
" In accordance with its favorable pharmacokinetic profile and in vitro potency, STAMP exhibited dose-dependent and potent in vivo anti-HIV activity in Hu-PBL-SCID mice against a genotypically and phenotypically nucleoside analog reverse transcriptase inhibitor (NRTI)-resistant clinical HIV type 1 (HIV-1) isolate (BR/92/019; D67N, L214F, T215D, K219Q) at nontoxic dose levels."( In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.
Chen, CL; Lisowski, E; Pendergrass, S; Qazi, S; Uckun, FM; Venkatachalam, TK; Waurzyniak, B, 2002
)
0.54
"5 months) underwent 18 intensive pharmacokinetic studies of nelfinavir and M8 at steady state."( Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Compagnucci, A; Faye, A; Giaquinto, C; Gibb, DM; Harper, L; Jacqz-Aigrain, E; Litalien, C, 2003
)
0.32
"Evaluate pharmacokinetic interaction, short-term safety, and antiretroviral activity of stavudine (d4T), nevirapine (NVP), and nelfinavir (NFV) as combination HIV-1 therapy."( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004
)
0.79
"Prospective, open-label study investigating the pharmacokinetic interactions between d4T, NVP, and NFV and documenting short-term tolerability and virologic and immunologic activity."( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004
)
0.57
" Steady-state pharmacokinetic parameters of NFV, AG1402 (metabolite of NFV), and d4T were compared before and after the addition of NVP."( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004
)
0.57
"NVP administration did not significantly affect the steady-state pharmacokinetic parameters of NFV or d4T."( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004
)
0.57
" Concentrations of the agents were quantitated at steady state after observed doses, and the pharmacokinetic parameters were determined."( Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Fletcher, CV; McIntosh, K; Nachman, SA; Pelton, S; Stanley, K; Wiznia, A; Yogev, R, 2004
)
0.55
"Therapy for HIV is complex, and pharmacodynamic data indicate that relationships exist between systemic concentrations of antiretroviral drugs and virologic response."( Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Fletcher, CV; McIntosh, K; Nachman, SA; Pelton, S; Stanley, K; Wiznia, A; Yogev, R, 2004
)
0.55
" Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83."( Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
Burchett, SK; Ciupak, G; Delke, I; Frenkel, L; Hitti, J; Huang, S; Mathias, A; Mofenson, L; Rathore, M; Samelson, R; Shapiro, DE; Smith, ME; Unadkat, JD; Wade, NA; Watts, DH; Yasin, S, 2004
)
0.61
"The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz."( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005
)
0.33
"This was a steady-state, open-label pharmacokinetic study of 19 patients."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
" The median (interquartile ranges) for indinavir AUC, Cmax and Cmin were 18."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
" Therapeutic Cmin levels of indinavir were achieved in >80% of the subjects and short-term virological response was satisfactory in this cohort of patients starting highly active antiretroviral therapy at an advanced disease stage with high baseline viral loads."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
"We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction."( No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005
)
0.33
" Pharmacokinetic parameters were dose proportional, and the maximum concentration of drug in serum at all doses exceeded the 90% effective concentration for wild-type HIV-1."( Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H, 2005
)
0.54
"The intracellular triphosphorylation and plasma pharmacokinetics of lamivudine (3TC), stavudine (d4T), and zidovudine (ZDV) were assessed in a pharmacokinetic substudy, in 56 human immunodeficiency virus-hepatitis C virus (HIV-HCV) coinfected patients receiving peginterferon alfa-2a (40KD) 180 microg/week plus either placebo or ribavirin (RBV) 800 mg/day in the AIDS PEGASYS Ribavirin International Coinfection Trial."( Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K, 2005
)
0.55
" Intensive pharmacokinetic sampling occurred after 4 weeks of therapy."( Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005
)
0.33
" NFV pharmacokinetic measurements were not statistically different between the treatment groups, yet exposure to the NFV metabolite, M8, was significantly higher in subjects receiving RTV."( Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005
)
0.33
" Dosage and dosing frequency did not influence clearance or volume of distribution of nevirapine, indicating linear pharmacokinetic behavior of nevirapine whether given as a single daily dose or as divided doses over 24 hours."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
" The Cmin of nevirapine is lower and the Cmax of nevirapine is higher for the once-daily regimen as compared to the twice-daily regimen."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
" The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased."( Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW, 2006
)
0.33
" Haematological changes, tissue distribution and pharmacokinetic studies of free, liposomal and mannosylated liposomal drug were performed following a bolus intravenous injection in Sprague-Dawley rats."( Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Agashe, HB; Agrawal, GP; Asthana, A; Garg, M; Jain, NK, 2006
)
1.78
" We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products."( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007
)
0.6
" An 8 h pharmacokinetic curve was recorded at day 1 of every cycle after medication intake."( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007
)
0.34
"Non-parametric statistical tests revealed no statistically significant differences in Cmax (0."( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007
)
0.34
"The pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune Baby and Junior are comparable to the branded products."( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007
)
0.62
" Patients taking Triomune had notably higher stavudine Cmax values."( Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Mshali, I; Phakati, S; Rezk, NL; van der Horst, C, 2007
)
0.83
"25h) in the body resulting in enhanced half-life of d4T (23."( Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes.
Dutta, T; Garg, M; Jain, NK, 2007
)
0.56
"To develop a population pharmacokinetic model for stavudine in children and to investigate the consistency of the currently recommended dose based on adult target concentrations."( Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.
Blanche, S; Bouillon-Pichault, M; Delaugerre, C; Dimet, J; Jullien, V; Pons, G; Raïs, A; Rey, E; Tréluyer, JM; Urien, S, 2007
)
0.84
"Twelve HIV-infected patients were assigned into a one-sequence, two-period pharmacokinetic interaction study."( Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
Jaruratanasirikul, S; Mahatthanatrakul, W; Ridtitid, W; Sriwiriyajan, S, 2007
)
0.34
" The pharmacokinetic profiles of D-DOT in serum and urine were adequately described by a two-compartment open pharmacokinetic model."( Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif, G; Chu, CK; Delinsky, D; Hurwitz, SJ; McClure, HM; Narayanasamy, J; Obikhod, A; Schinazi, RF, 2007
)
0.34
" Several phase I studies were conducted in healthy volunteers over the course of clinical development to evaluate whether pharmacokinetic drug-drug interactions exist between emtricitabine and other nucleoside antivirals that are extensively eliminated by renal excretion."( Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers.
Begley, JA; Blum, MR; Chittick, GE; Hui, J; Wang, LH; Zong, J, 2007
)
0.34
"This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates."( Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Diquet, B; Goujard, C; Legrand, M; Mentré, F; Panhard, X; Taburet, AM, 2007
)
0.81
" After 4 weeks or more, a 12-h pharmacokinetic curve was recorded."( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008
)
0.72
"Nevirapine concentrations were higher but more variable than in adults; the pharmacokinetic parameters of stavudine and lamivudine were comparable to adults."( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008
)
0.94
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans."( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008
)
0.79
" Similarity between steady-state pharmacokinetic parameters was assessed using the US Food and Drug Administration standards for bioequivalency testing."( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008
)
0.57
" Pharmacokinetic parameter inter-individual variability ranged from 29% to 99%."( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008
)
0.57
" Capacity building for pharmacokinetic research in resource-limited settings is a priority."( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008
)
0.57
" The effect of three routinely prescribed antiretroviral (ARV) drugs on the pharmacokinetic profile of an antidiabetic drug, chlorpropamide, was investigated in 18 human subjects, who had recently been diagnosed positive for human immunodeficiency virus (HIV) infection."( The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects.
Bakare-Odunola, MT; Enemali, I; Garba, M; Mustapha, KB; Obodozie, OO,
)
0.42
" The method has been successfully applied to the pharmacokinetic study of a combination treatment of 300 mg lamivudine, 30 mg stavudine and 200 mg nevirapine in 22 healthy male volunteers under fasting conditions."( Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC-MS/MS and its application to pharmacokinetic study in clinic.
Ding, C; Ge, Q; Li, Z; Liu, X; Zhi, X; Zhou, Z, 2010
)
0.83
" After 10 days of one formulation, 6-h pharmacokinetic sampling was performed, and patients were crossed over to subsequent formulations."( Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010
)
0.6
"Full 12-hour pharmacokinetic profiles of nevirapine, stavudine, and lamivudine in HIV-infected children taking fixed-dose combination antiretroviral tablets have been reported previously by us."( Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
Burger, D; Chintu, C; Ewings, F; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, R; Mulenga, V; Thomason, M; Walker, AS, 2010
)
0.84
"The International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT) P1056 study was a phase I/II, 2-arm, randomized, open-label, multidose pharmacokinetic cross-over study."( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010
)
0.61
" This approach is based on the pharmacokinetic simulation of drug plasma levels through a semiparametric approach of the input function and on convolution with an empirical polyexponential unit impulse response function."( Optimization of release kinetics from sustained-release formulations using model-independent pharmacokinetic simulation.
Lanao, JM; Maderuelo, C; Zarzuelo, A, 2011
)
0.37
" The method was successfully applied to quantify them in a rat pharmacokinetic study in whole blood, plasma and DBS cards after a single oral co-administration at the dose of 10, 2 and 13 mg/kg for lamivudine, stavudine and nevirapine, respectively, to male Wistar rats."( Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study.
Aleti, R; Bhyrapuneni, G; Kalaikadhiban, I; Kandikere, V; Komarneni, P; Muddana, N; Nirogi, R; Padala, N, 2012
)
0.78
"Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling."( Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012
)
0.38
" But there are limited pharmacokinetic data evaluating the higher dose of rifabutin in combination with LPV/r."( Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014
)
0.4
" The median AUC0-48 and Cmax of rifabutin in patients taking 150 mg rifabutin tiw was significantly reduced compared to the other treatment arms."( Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014
)
0.4
" A physiologically-based pharmacokinetic model consisting of 13 tissue compartments plus a full ADAM model was used to describe the elimination of stavudine."( Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.
Asin-Prieto, E; Cotton, MF; Derendorf, H; Innes, S; Malmberg, R; Matsushima, A; Rosenkranz, B; Sy, SK, 2015
)
0.9
"The in vitro-in vivo pharmacokinetic correlation models (IVIVC) are a fundamental part of the drug discovery and development process."( In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs.
Restrepo Valencia, P; Rojas Gómez, R, 2015
)
0.42
"To develop a comprehensive model to predict the in vivo absorption of antiretroviral drugs based on permeability studies, in vitro and in vivo solubility and demonstrate its correlation with the pharmacokinetic profile in humans."( In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs.
Restrepo Valencia, P; Rojas Gómez, R, 2015
)
0.42

Compound-Compound Interactions

The 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with HIV-1. Three dose levels of the protease inhibitor (PI) atazanavir were compared with nelfinavir.

ExcerptReferenceRelevance
" Additive antiviral activity was observed with L(-)Fd4C in combination with 2',3'-dideoxycytidine (ddC, or zalcitabine) or 2',3'-dideoxyinosine (ddI, or didanosine)."( Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Bridges, EG; Cheng, YC; Dutschman, GE; Gullen, E; Guo, X; Kukhanova, M; Liu, SH, 1998
)
0.3
" Ten patients with CD4 counts of less than 200 cells/mm3 received stavudine (40 mg twice daily) in combination with one to three other drugs used to treat opportunistic infections."( A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.
Davey, RT; Falloon, J; Kelly, G; Kovacs, J; Masur, H; Piscitelli, SC; Polis, MA; Raje, S; Walker, RE, 1999
)
0.81
"To compare the antiviral activity of once-daily didanosine (ddI) and twice-daily ddI in combination with stavudine (d4T)."( Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
Adler, MH; Kelleher, T; McLaren, C; Mobley, JE; Pollard, RB; Schrader, S, 1999
)
0.74
"Patients received once-daily ddI or twice-daily ddI, each combined with twice-daily d4T."( Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
Adler, MH; Kelleher, T; McLaren, C; Mobley, JE; Pollard, RB; Schrader, S, 1999
)
0.52
"Nelfinavir is a novel protease inhibitor that exhibits good inhibitory activity against human immunodeficiency virus type 1 (HIV-1) and is currently used in combination with reverse transcriptase inhibitors for the management of HIV infection."( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000
)
0.54
"To compare the antiviral activity, safety and tolerability of didanosine dosed once and twice daily when administered in combination with stavudine dosed twice daily in human immunodeficiency virus type 1 (HIV-1)-infected individuals with little or no previous exposure to antiretroviral drugs."( Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
Angarano, G; Cargnel, A; Chirianni, A; Di Stefano, M; Ferraro, T; Monno, L; Soranzo, ML, 1999
)
0.74
"To compare the safety and efficacy of stavudine (d4T) + lamivudine (3TC) with zidovudine (ZDV) + 3TC, each in combination with indinavir (IDV)."( A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B, 2000
)
0.92
"These results support the choice of d4T + 3TC as a nucleoside analog pair in combination with a protease inhibitor in an initial HIV treatment regimen."( A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B, 2000
)
0.65
" In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
" The first 40 patients entered onto the study received reduced doses of cyclophosphamide and doxorubicin, combined with vincristine and prednisone (modified CHOP [mCHOP]), whereas the subsequent 25 patients entered onto the study received full doses of CHOP combined with granulocyte colony-stimulating factor (G-CSF)."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
" Eight neonates born to human immunodeficiency virus-infected mothers were enrolled to receive 1 mg of d4T per kg of body weight twice daily and 100 mg of ddI per m(2) once daily in combination with nelfinavir for 4 weeks after birth."( Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Boonrod, C; Chuenyam, T; Cooper, DA; Damle, BD; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P, 2001
)
0.63
"Triple drug combination regimen the most often was composed of: either AZT + 3TC + NFV, ddi + d4T + NFV, or ddI + d4T + NVP."( [Drug combination therapy for children infected with HIV/AIDS--own experience].
Klinowska-Skupniewska, J; Prandota-Schoepp, A, 2001
)
0.31
"We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine (ddC)-experienced patients in a randomized comparative multicenter trial."( Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir tria
Aboulker, JP; Brun-Vezinet, F; Certain, A; Descamps, D; Flandre, P; Gastaut, JA; Goujard, C; Joly, V; Meiffredy, V; Remy, G; Ruffault, A; Yeni, P, 2002
)
0.83
"The authors studied the effect of zidovudine (ZDV) resistance mutation on virologic response to treatment with ZDV or stavudine (d4T) each in combination with lamivudine and indinavir."( Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Harel, M; Izopet, J; Joly, V; Lastère, S; Meiffrédy, V; Peytavin, G; Tamalet, C; Yéni, P; Zeng, AF, 2002
)
0.74
"Three dose levels of the protease inhibitor (PI) atazanavir (200, 400, and 500 mg once daily) were compared with nelfinavir (750 mg three times daily) when given both as monotherapy and in combination with didanosine and stavudine in 420 antiretroviral-naive subjects infected with HIV-1."( Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Piliero, P; Sanne, I; Schnittman, S; Squires, K; Thiry, A, 2003
)
0.7
"The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated."( Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Andron, L; Asmuth, DM; Grady, JJ; Green, S; McKinsey, DS; Pollard, RB; Rossero, R, 2003
)
0.81
" In this study, the anti-HIV-1 activity of EMV in combination with two nucleoside reverse transcriptase inhibitors was examined in cell cultures."( Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Baba, M; Nitanda, T; Somekawa, K; Wang, X; Yuasa, S, 2001
)
0.31
"To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
" The combined results of the three trials support the conclusion that d4T can be used effectively in combination with either ddI or 3TC to reduce viral loads and increase CD4 cell counts in patients with HIV-1 infection."( Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
Fisher, M, 1998
)
0.54
"The combination of abacavir + lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA >50 copies/mL (at or after the 8-month visit) or death (primary endpoint) in a nested substudy of an ongoing multicenter randomized trial."( Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.
Besch, L; Chen, L; Dehlinger, M; Henley, C; Kozal, M; MacArthur, RD; Novak, RM; Peng, G; Schmetter, B; van den Berg-Wolf, M; Yurik, T,
)
0.6
"We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction."( No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005
)
0.33
"Emtricitabine is a potent nucleoside reverse transcriptase inhibitor approved as a once-daily drug in combination with other antiretroviral agents for the treatment of HIV infection."( Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers.
Begley, JA; Blum, MR; Chittick, GE; Hui, J; Wang, LH; Zong, J, 2007
)
0.34
" We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV)."( Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.
Bae, AS; Borroto-Esoda, K; Harris, JL; Hinkle, JE; Quinn, JB; Rousseau, FS; Waters, JM, 2007
)
0.77
"Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC) and efavirenz (EFV), and an ongoing 336-week open-label extension phase."( The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Holmes, CB; Madruga, JR; Suleiman, JM; Zhong, L,
)
0.62
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
"This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine."( Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Mathew, M; McComsey, G; McGrath, D; Rightmire, A; Wirtz, V; Yang, R, 2009
)
0.74
"To assess the efficacy of d4T compared to AZT in combination with one NRTI and one non-nucleoside reverse transcriptase inhibitor (NNRTI), two additional NNRTIs, or one NRTI and one protease inhibitor (PI), as part of first-line ART for HIV-infected people in low-resource settings."( Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
Rutherford, GW; Siegfried, N; Spaulding, A, 2010
)
1.8

Bioavailability

The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2',3'-dideoxy-3'-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex.

ExcerptReferenceRelevance
" The absolute bioavailability of a 4 mg/kg oral dose exceeded 80%."( Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.
Browne, M; Dudley, MN; Dunkle, L; Geletko, S; Graham, KK; Kaul, S; Mayer, K, 1992
)
0.61
" Oral bioavailability of 3'-deoxy-2',3'-didehydrothymidine was incomplete, with an average of 42% +/- 15% of the dose reaching the systemic circulation."( Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.
Boudinot, FD; Doshi, KJ; McClure, HM; Schinazi, RF, 1990
)
0.28
" The absolute oral bioavailability of the drug ranged from 61% to 78%."( A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
Church, JA; Dunkle, LM; Federici, ME; Goldsmith, JC; Harris, AT; Kaul, S; Kline, MW; Loewen, DF; Schultze, ME; Woods, L, 1995
)
0.59
" The relative bioavailability estimates and 90% confidence limits for the dose-normalized Cmax values with the 10 mg capsule as the reference were 86% (76%, 96%), 99% (88%, 110%), and 90% (80%, 100%) for the 5, 20, and 40 mg capsules, respectively."( Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations.
Barbhaiya, RH; Kaul, S; Mummaneni, V, 1995
)
0.6
" The relative oral bioavailability of methoxy acetate 3 and cyclohexyl carbonate 5 was 79 and 41%, respectively."( Prodrugs of 2',3'-didehydro-3'-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation.
Ghazzouli, I; Hitchcock, MJ; Mansuri, MM; Martin, JC; Russell, JW; Starrett, JE; Tortolani, DR; Whiterock, VJ, 1994
)
0.29
" Mean oral bioavailability of D4T was high at approximately 70%."( In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine.
Cretton, EM; Hitchcock, MJ; Kaul, S; Kidd, LB; McClure, HM; Sommadossi, JP; Zhou, Z, 1993
)
0.29
"83 h, a urinary recovery of 44%, and an oral bioavailability of 80%."( Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.
Dandekar, KA; Kaul, S, 1993
)
0.52
" In clinical studies, stavudine has excellent oral bioavailability in excess of 80%."( Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).
Anderson, RE; Mellors, JW; Riddler, SA, 1995
)
0.9
"The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2',3'-dideoxy-3'-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex (ARC) enrolled in phase I and phase I/II dose-ranging trials."( Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.
Anderson, R; Dudley, MN; Dunkle, L; Horton, CM; Kaul, S; Mayer, KH; Squires, K, 1995
)
0.82
" The low hybrid K(m) and high passive permeability of d4T likely account for the lack of saturable absorption behavior observed in humans, whereas the brush-border and intracellular stability of d4T preserve the high bioavailability observed after oral dosing."( Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations.
Sinko, PJ; Waclawski, AP, 1996
)
0.5
" AZT and D4T were rapidly absorbed from the gastrointestinal tract and their bioavailability was more than 90%."( Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
Hasegawa, T; Juni, K; Kawaguchi, T; Saneyoshi, M, 1996
)
0.29
" Bioavailability of D4T following intranasal (i."( Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats.
Hasegawa, T; Juni, K; Kawaguchi, T; Saneyoshi, M; Yajima, T, 1996
)
0.29
" The absolute oral bioavailability is high, approaching 100%."( Clinical pharmacokinetics of stavudine.
Dudley, MN; Rana, KZ, 1997
)
0.59
" D4T was rapidly absorbed with an absolute oral bioavailability ranging from 77 to 100% in various species."( Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).
Barbhaiya, RH; Dandekar, KA; Kaul, S; Schilling, BE, 1999
)
0.55
" ACTG 333 tested the consequences of long-term use of hard capsule saquinavir, and found that it is poorly absorbed and there is only a very modest effect on HIV."( Spring cleaning in trial land.
Gilden, D, 1997
)
0.3
" Volume of distribution and absorption rate constant were 77."( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005
)
0.33
" Following IN administration, d4T was rapidly and completely absorbed into the systemic circulation with a T(max) of 14 min and an IN bioavailability of 105%."( Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats.
Gan, G; Huang, Y; Sawchuk, RJ; Yang, Z, 2005
)
0.58
"An open-label, balanced, randomized, 2-treatment, 2-period, 2-sequence, single-dose, crossover bioavailability study was conducted in 40 subjects with 21-day washout period between each treatment."( Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
Garg, M; Monif, T; Singla, AK; Tippabhotla, SK; Vijan, T, 2006
)
0.65
"The aim of this study was to compare the single-dose oral bioavailability of two formulations of stavudine 40 mg capsules in healthy human subjects."( Comparative bioavailability/bioequivalence of two different stavudine 40 mg capsule formulations: a randomized, 2-way, crossover study in healthy volunteers under fasting condition.
Garg, M; Monif, T; Singla, AK; Tippabhotla, SK, 2007
)
0.8
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The method was successfully applied to a bioavailability study of a combined tablet formulation containing 30 mg of stavudine and 150 mg of lamivudine compared with each reference formulation concurrently administered in 26 healthy Thai male volunteers."( Simultaneous determination of stavudine and lamivudine in human plasma by high performance liquid chromatography and its application to a bioavailability study.
Akarawut, W; Prasanchaimontri, IO; Wattananat, T, 2010
)
0.86
" The bioavailability of stavudine using the opened capsule dosing method has not previously been validated."( Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
Capparelli, E; Cotton, M; Innes, S; Norman, J; Rosenkranz, B; Smith, P; Smuts, M, 2011
)
0.97
" These IVIVC models are proposed as alternative and cost/effective methods to evaluate the biopharmaceutical properties that determine the bioavailability of a drug and their application includes the development process, quality assurance, bioequivalence studies and pharmacosurveillance."( In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs.
Restrepo Valencia, P; Rojas Gómez, R, 2015
)
0.42
" Formulations containing 1 % Poloxamer 188 exhibited enhanced in vivo absorption and hence could be used once daily in order to enhance the bioavailability of this drug."( Application of SRMS 154 as Sustained Release Matrix for the Delivery of Stavudine:
Attama, AA; Chime, SA; Onunkwo, GC, 2020
)
0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Proficient bioavailability coupled with no predicted in silico toxicity rendered them as prospective alternatives for designing and development of novel combinatorial therapy formulations for improving existing treatment regimes to combat COVID-19."( Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
Banerjee, DI; Darji, SA; Lipsa Rath, S; Toor, HG, 2021
)
0.62

Dosage Studied

Stavudine was found to be bioequivalent to intact capsule administration in HIV-seronegative adults. The opened capsule dosing technique is bioequ equivalent to intact capsules dosing for stavUDine in HIV+ adults.

ExcerptRelevanceReference
"67, or 4 mg/kg of body weight; 17 of them underwent an additional steady-state pharmacokinetic evaluation after thrice-daily dosing of the above doses."( Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.
Browne, M; Dudley, MN; Dunkle, L; Geletko, S; Graham, KK; Kaul, S; Mayer, K, 1992
)
0.61
" Measurements of phosphorylated zidovudine inside cells similarly suggest that 100 mg of oral zidovudine every 8 hours approximates the optimal initial dosage regimen in asymptomatic patients."( Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Stretcher, BN, 1995
)
0.29
" The study was designed to evaluate the activity of stavudine after 10 weeks of therapy and permitted extended dosing and follow-up for long-term safety."( Dose-related activity of stavudine in patients infected with human immunodeficiency virus.
Anderson, RE; Cross, A; Dunkle, LM; Follansbee, S; Hardy, WD; Petersen, EA; Peterson, DM; Ramírez-Ronda, CH; Sacks, HS; Schwartz, R, 1995
)
0.85
" The effect of the dosing regimen was measured with viral infectivity, p24 antigen, and reverse transcriptase or PCR for unintegrated HIV DNA."( Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.
Bauer, G; Bilello, JA; Cole, GA; Drusano, GL; Dudley, MN, 1994
)
0.29
" The area under plasma ddN concentration curve (AUC) and the residual percent of dose 1 h after dosing indicated a greater absorption of AZT and D4T in the upper intestinal tract than in the colon, very poor absorption of DDI in all segments, and considerable absorption of AZT in the colon."( Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
Hasegawa, T; Juni, K; Kawaguchi, T; Saneyoshi, M, 1996
)
0.29
" This suggests that C2-D4T was rapidly absorbed from the nasal cavity, and that some amount of dosing C2-D4T was hydrolyzed to D4T before entering the systemic circulation."( Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats.
Hasegawa, T; Juni, K; Kawaguchi, T; Saneyoshi, M; Yajima, T, 1996
)
0.29
" Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease."( Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
Christofalo, B; Grasela, DM; Petty, BG; Raymond, R; Schaad, HJ; Stewart, M, 1997
)
0.85
" Blood samples were collected over an 8-hour period after dosing and included a sample simultaneous with CSF collection to permit an estimate of CSF : plasma ratios."( A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.
Anderson, RD; Christofalo, B; Dunkle, LM; Haworth, SJ, 1998
)
0.55
" However, trends toward greater decreases in viral load and increases in CD4 count were detected when treatment groups containing the full recommended dosage of one or both agents (high-dose subgroup; arms 3, 4, and 5) were compared with the groups receiving lower dosages."( Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.
Beall, G; Cross, AP; Dunkle, LM; Gathe, J; Hardy, D; Murphy, RL; Peterson, D; Pollard, RB; Pottage, J; Reynolds, L; Rutkievicz, V, 1999
)
0.54
"The indinavir dosage regimen currently used for human immunodeficiency virus (HIV)-infected children is not based on pharmacokinetic data obtained in the target patient population."( Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Bassetti, D; Bassetti, M; Gatti, G; Principi, N; Sala, N; Vella, S; Vigano', A, 2000
)
0.31
"25 mg/L and the mean AUC during the dosing interval was 17."( Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P, 2000
)
0.54
"The use of human immunodeficiency virus (HIV) protease inhibitors in children has lagged behind that in adults because of the lack of suitable pediatric formulations and information on safe and effective dosing regimens."( Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
Brundage, RC; Calles, NR; Fletcher, CV; Kline, MW; Page, LM; Remmel, RP; Simon, C; Weller, D, 2000
)
0.55
"To compare the antiviral activity, safety and tolerability of didanosine dosed once and twice daily when administered in combination with stavudine dosed twice daily in human immunodeficiency virus type 1 (HIV-1)-infected individuals with little or no previous exposure to antiretroviral drugs."( Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
Angarano, G; Cargnel, A; Chirianni, A; Di Stefano, M; Ferraro, T; Monno, L; Soranzo, ML, 1999
)
0.74
" The following stavudine dosage recommendations for renal impairment were proposed for subjects weighing >/=60 kg: CL(CR) of >50 ml/min/1."( Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
Barry, M; Bone, M; Grasela, DM; Haworth, SJ; Mangold, B; O'Grady, P; Raymond, R; Stoltz, RR, 2000
)
0.93
"NVP reaches concentrations in the semen approximately 60% of those in the blood plasma throughout the 12 h dosing period."( Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
Drake, SM; Hoetelmans, RM; Pillay, D; Taylor, S; van Heeswijk, RP; White, DJ; Workman, J, 2000
)
0.57
" The study was designed to demonstrate that once-daily dosing of ddI was not inferior to twice-daily dosing."( Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
Belec, L; Costagliola, D; Kazatchkine, MD; Ledeine, JM; Mohammed, AS; Troccaz, M; Van, PN, 2000
)
0.31
" Hydroxyurea was held temporarily during the first month of therapy in 4 cases because of neutropenia; all patients resumed hydroxyurea at full dosage without recurrence of neutropenia."( Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
Calles, NR; Kline, MW; Schwarzwald, H; Simon, C, 2000
)
0.52
" d4TTP reached its highest level 2 to 4 h after dosing (0."( Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.
Back, DJ; Carey, P; Hart, CA; Hoggard, PG; Khoo, SH; Lloyd, J; Maher, BA; Phiboonbanakit, D; Sales, SD; Wilkins, E, 2001
)
0.57
" Plasma trough levels of nelfinavir (NFV) and saquinavir (SQV), in a twice daily dosing regimen, were above the protein-corrected IC(95) in most patients despite the addition of an enzymatic inducer such as nevirapine, and peak levels were 2- and 5-fold increased with respect to standard doses."( Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001
)
0.55
"The results of the development of dosing guidelines for stavudine in human immunodeficiency virus (HIV)-infected children are summarized."( Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection.
Church, JA; Dunkle, LM; Kaul, S; Kline, MW, 2001
)
0.83
" Findings from studies for each drug in such areas as the drug's purpose, dosage level, effectiveness, and side effects are examined."( What we know about anti-HIV drugs.
, 1995
)
0.29
" Conant's interview, in which the dosage level of d4T was confusing to readers."( d4T dose clarification.
James, JS, 1995
)
0.29
" All participants received some of each drug, but since the trial is ongoing, assignments are still blinded, so dose-response information on antiviral activity is not yet available."( d4T plus ddI antiviral results.
, 1996
)
0.29
"A study of 85 volunteers divided into 5 separate dosage groups found fairly good viral suppression from a combination of didanosine plus stavudine."( ddI plus d4T.
James, JS, 1996
)
0.5
" Dosage regimens are as follows: saquinavir, 3 capsules every 8 hours with food; ritonavir, 6 capsules every 12 hours with food; and indinavir, 2 capsules every 8 hours on an empty stomach."( A patient's guide to protease inhibitors.
Elperin, A; Sax, P, 1996
)
0.29
" A recommended dosage schedule for ddI and d4T combined with indinavir is provided."( ddI and d4T plus protease inhibitors.
, 1996
)
0.29
" Combining d4T/ddI with protease inhibitors presents problems, such as a complicated dosing schedule and harsh gastrointestinal side effects."( Dethroning AZT.
Falkenberg, J; Gilden, D; Torres, G, 1997
)
0.3
" Study results of twice-daily dosing regimens of indinavir and nelfinavir look promising."( Drug research shows easier dosing, new combinations are making gains.
, 1998
)
0.3
" Hydroxyurea's dosage level is still uncertain; 500 mg twice daily has been used most often."( Hydroxyurea for HIV infection.
Davis, B; Zachary, KC, 1998
)
0.3
" Food restrictions, drug interactions, dosing requirements, and side effects may make a particular regimen less desirable."( Reevaluating initial therapy.
Cadman, J, 1998
)
0.3
" Hydroxyurea's side effects, dosage requirements, and method of reducing HIV in the body are discussed."( Hydroxyurea for HIV?
, 1998
)
0.3
" This case involves a 38-year-old, HIV-positive male who, in response to numbness in his left foot, reduced his dosage of d4T by half, without consulting his physician."( Too little of a good thing.
Friedland, GH; Gulick, RM, 1998
)
0.3
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."( What they say about: nucleoside drugs.
,
)
0.13
"The complexity of highly active antiretroviral therapy (HAART), with multiple medications, formulations, and dosing intervals, makes adherence challenging."( Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A, 2002
)
0.31
" The highly variable systemic exposure observed in the study indicates that therapeutic drug monitoring seems warranted to ensure adequate NFV dosing in this population."( Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Boonrod, C; Chuenyam, T; Cooper, DA; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P; Ubolyam, S; van Heeswijk, RP, 2002
)
0.31
" The second episode ended when lamivudine dosage was reduced."( Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy.
Livrozet, JM; Miossec, P; Touraine, JL; Wegrzyn, J, 2002
)
0.31
"In children younger than 2 years of age vertically infected with HIV-1, the recommended pediatric dosing regimen for nelfinavir (20 to 30 mg/kg three times a day) provides insufficient drug exposure."( Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Compagnucci, A; Faye, A; Giaquinto, C; Gibb, DM; Harper, L; Jacqz-Aigrain, E; Litalien, C, 2003
)
0.32
"A powerful statistical method was designed using JMP software to detect factors contributing to differences in the dissolution process of an antiviral drug delivered in an oral dosage form."( Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software.
Qazi, S; Samuel, NK; Uckun, FM; Venkatachalam, TK, 2003
)
0.32
"7 h after the last ZDV dosing in 31 patients."( Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients.
Becher, F; Benech, HC; Créminon, CA; Delfraissy, JF; Goujard, CM; Grassi, JJ; Pruvost, AG; Schlemmer, DD, 2003
)
0.59
" After 48 weeks, LPV/r was dosed open-label at 400/100 mg every 12 hours with stavudine and lamivudine."( Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Benson, C; Brun, SC; Eron, JJ; Gulick, RM; Hicks, C; Kessler, HA; King, KR; King, MS; Murphy, RL; White, AC, 2004
)
0.55
" Fifteen patients in the long-term treatment group and all 15 patients in the single-dose treatment group were randomized to undergo lumbar puncture 2, 4, or 6 hours after dosing (five patients for each time point from each group)."( Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus.
Aldrich, JL; Boston, RC; Brady, KA; MacGregor, RR, 2005
)
1.77
"Serum stavudine concentrations were obtained just before dosing, 1 hour after dosing (approximate peak), and at the time of lumbar puncture."( Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus.
Aldrich, JL; Boston, RC; Brady, KA; MacGregor, RR, 2005
)
2.25
" One group of animals received IN administration of 5 mg/kg d4T (50 microL); the other group was dosed intravenously (IV) at the same dose."( Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats.
Gan, G; Huang, Y; Sawchuk, RJ; Yang, Z, 2005
)
0.58
"The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination."( Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005
)
0.33
" Additional studies will determine the optimum dosage and schedule for hydroxyurea and its effects when used with other agents and in patients with advanced disease or extensive pretreatment."( Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lisziewicz, J; Lori, F, 1999
)
0.3
"To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen."( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM,
)
0.35
"HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or simplified once-daily dosed antiretroviral regimens consisting of nevirapine, didanosine, and lamivudine (regimen B) or saquinavir, ritonavir, didanosine, and lamivudine (regimen C)."( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM,
)
0.57
"No statistically significant difference in efficacy was found between the two investigated once-daily dosed treatment regimens (B and C) and the reference (A)."( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM,
)
0.35
"As part of the large international, randomized 2NN trial, the pharmacokinetics of nevirapine in once-daily 400 mg and twice-daily 200 mg dosing regimens were investigated."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
" Differences in pharmacokinetics between once- versus twice-daily dosing were investigated with nonlinear mixed effects modelling (NONMEM)."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
" Dosage and dosing frequency did not influence clearance or volume of distribution of nevirapine, indicating linear pharmacokinetic behavior of nevirapine whether given as a single daily dose or as divided doses over 24 hours."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
"The daily exposure to nevirapine (AUC24h) was similar for the 400 mg once-daily and the 200 mg twice-daily dosing regimens."( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F,
)
0.13
" The method has been successfully used to analyze commercial dosage form to assess the chromatographic performance of SFC system which was found to be 99."( Effect of system variables involved in packed column supercritical fluid chromatography of stavudine taken as model analyte using response surface methodology along with study of thermodynamic parameters.
Agrawal, H; Kaul, N; Mahadik, KR; Paradkar, AR, 2007
)
0.56
" Based on these results, it is acceptable to test the pharmacokinetics and dosing requirements of Pedimune in HIV-infected children."( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007
)
0.34
"Our findings support the current recommended paediatric dosage regimens for stavudine, as they result in the same exposure to the drug as in adults."( Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.
Blanche, S; Bouillon-Pichault, M; Delaugerre, C; Dimet, J; Jullien, V; Pons, G; Raïs, A; Rey, E; Tréluyer, JM; Urien, S, 2007
)
0.82
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" The dosing was too low for 18% of the patients and too high for 39% of the patients."( Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis.
Bagnis, CI; Bessette, C; Deray, G; Karie, S; Launay-Vacher, V; Tézenas Du Montcel, S; Tostivint, I; Tourret, J; Vigneau, C, 2007
)
0.34
" In conclusion, with the persistence of 4'-Ed4TTP and persistent anti-HIV activity in cells, we anticipate less frequent dosing and fewer patient compliance issues than for D4T."( Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
Baba, M; Cheng, YC; Dutschman, GE; Grill, SP; Hu, R; Lam, W; Paintsil, E; Tanaka, H, 2007
)
0.34
" TDM is useful to determine the best dosage regimen adapted to each patient."( Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M, 2008
)
0.57
"Seventy-one Zambian children were treated with Triomune Baby or Junior dosed according to weight bands."( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008
)
0.72
"Four sensitive and rapid methods for the determination of stavudine (STV) in bulk drug and in dosage forms were developed and optimized."( Sensitive and rapid titrimetric and spectrophotometric methods for the determination of stavudine in pharmaceuticals using bromate-bromide and three dyes.
Basavaiah, K; Kumar, UR; Ramakrishna, V; Somashekar, C, 2008
)
0.81
"In antiretroviral (ARV) therapy, pill burden, dosing frequency, and regimen complexity adversely affect adherence."( Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.
Boyle, BA; Grimm, K; Jayaweera, D; Maa, JF; Seekins, DW; Witt, MD,
)
0.43
" Further exploration of regimens and dosing of antiretrovirals for children in these settings is needed."( Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Berrisford, AE; Boulle, AM; Jaspan, HB, 2008
)
0.35
"Children were recruited in weight-based dosage bands and nutritional status classified according to weight for height."( Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009
)
0.35
" Before dosing humans with [1'-(14)C]stavudine, a tissue distribution study was performed in Long-Evans rats."( Disposition of [1'-(14)C]stavudine after oral administration to humans.
Espina, RR; Iyer, RA; Kaul, S; Liu-Kreyche, P; Roongta, VA; Tran, SB; Warrack, BM; Zhou, L, 2010
)
0.94
" Children were stratified by weight and dosing was weight-based."( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010
)
0.61
"CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines."( Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
Chintu, C; Ferrier, A; Ford, D; Gibb, DM; Grant, PR; Gupta, RK; Kabamba, D; Kalumbi, M; Mulenga, V; Pillay, D; Walker, AS, 2010
)
0.57
" Children taking T30 for > 6 weeks from each dosing weight band (<5, 5-<8, 8-<12, 12-<14, 14-<19, 19-<26, 26-<30 and > or = 30 kg) were recruited."( Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
Burger, D; Chesshyre, E; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L, 2010
)
0.63
"Children were randomized to initiate antiretroviral therapy with full-dose (FD) nevirapine (Triomune Baby or Junior in the morning and evening) versus DE (half-dose nevirapine for 14 days [Triomune in the morning and stavudine-lamivudine {Lamivir-S} in the evening], then FD), in accordance with World Health Organization weight-band dosing tables."( Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS, 2010
)
0.55
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment."( Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010
)
0.99
"The use of d4T at a lower dosage might increase safety with regard to its effect on lipoatrophy."( Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010
)
0.71
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing stavudine (d4T) are reviewed."( Biowaiver monographs for immediate-release solid oral dosage forms: stavudine.
Barends, DM; Cristofoletti, R; Dressman, JB; Junginger, HE; Shah, VP; Silva, AL; Sousa, VD; Stavchansky, S; Storpirtis, S, 2012
)
0.81
" The paediatric liquid formulation presents major logistical difficulties in rural and resource-limited areas, and prescribers are frequently forced to employ off-label 'opened capsule' dosing methods using the adult capsule."( Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
Capparelli, E; Cotton, M; Innes, S; Norman, J; Rosenkranz, B; Smith, P; Smuts, M, 2011
)
0.66
"Plasma drug exposure after stavudine administration as a solution using an opened capsule dosing method was found to be bioequivalent to intact capsule administration."( Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
Capparelli, E; Cotton, M; Innes, S; Norman, J; Rosenkranz, B; Smith, P; Smuts, M, 2011
)
0.96
"The opened capsule dosing technique is bioequivalent to intact capsule dosing for stavudine in HIV-seronegative adults."( Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
Capparelli, E; Cotton, M; Innes, S; Norman, J; Rosenkranz, B; Smith, P; Smuts, M, 2011
)
0.89
" Information on how polymorphisms influence drug metabolism and transport to target sites is important in guiding dosage or selection of appropriate alternative therapies."( Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
Bessong, PO; Masebe, TM; Meyer, D; Ndip, RN; Nwobegahay, J, 2012
)
0.38
"Lower stavudine dosage is associated with fewer reports of several stavudine-associated adverse events and also a lower risk of stavudine discontinuation within the first year on ART."( Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.
Fox, MP; Maotoe, T; Maskew, M; Sanne, IM; Westreich, D, 2012
)
1.12
" Stavudine dosage was 30 mg irrespective of weight."( Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi.
Chagoma, N; Heyderman, RS; Kampira, E; Kaunda, S; Mallewa, J; Mukaka, M; Njalale, Y; van Oosterhout, JJ, 2012
)
2.73
" Through dose-response experiments, we established relative inhibitory potencies of NRTIs on in vitro telomerase activity as compared to the inhibitory potencies of the corresponding dideoxynucleotide triphosphates."( In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM, 2012
)
0.38
" These were twice daily dosing schema at a time when most formulations were long-life allowing once daily dosing; and that the use of d4T IR was associated with long-term toxicity through mitochondrial toxicity clinically expressed as peripheral neuropathy, pancreatitis and above all, lipodystrophy."( Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.
Domingo, P; Gutierrez, Mdel M; Mateo, MG; Vidal, F, 2013
)
1.83
" Some studies suggested weight-adjusted AZT dosing as a way to reduce toxicity."( Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.
Lynen, L; Phe, T; Sok, S; Thai, S; van Griensven, J; Veng, C, 2013
)
0.62
"Our findings argue against the need of weight-based dosing of AZT to reduce anemia among patients using AZT as substitution for D4T."( Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.
Lynen, L; Phe, T; Sok, S; Thai, S; van Griensven, J; Veng, C, 2013
)
0.62
" Sub-optimal dosing can lead to acquired rifamycin resistance (ARR)."( Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014
)
0.4
" Plasma d-RBT concentrations increased 5-fold with tiw rifabutin dosing and 15-fold with daily doses of rifabutin."( Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014
)
0.4
" Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection."( Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
Priya, MR; Rajendran, NN, 2015
)
1.6
" Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines."( Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS, 2016
)
0.74
" Gelatin nanoformulations containing very low dosage of stavudine were prepared through classical desolvation process and were later loaded in soya lecithin-liposomes."( Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation.
Ashe, S; Boxi, A; Nayak, B; Nayak, D; Thathapudi, NC, 2017
)
2.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
dihydrofuranCompounds containing a mono-unsaturated furan ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.14590.003245.467312,589.2998AID2517
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
endonuclease IVEscherichia coliPotency0.00010.707912.432431.6228AID1708
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
Smad3Homo sapiens (human)Potency14.12540.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency29.79750.001022.650876.6163AID1224838; AID1224893
EWS/FLI fusion proteinHomo sapiens (human)Potency34.04290.001310.157742.8575AID1259252
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.07950.000214.376460.0339AID588532
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.37390.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.06120.000229.305416,493.5996AID743075
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.06310.035520.977089.1251AID504332
Histone H2A.xCricetulus griseus (Chinese hamster)Potency22.89430.039147.5451146.8240AID1224845; AID1224896
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.79430.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00350.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.80480.00419.984825.9290AID504444
DNA polymerase betaHomo sapiens (human)Potency79.43280.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency0.70790.133725.412989.1251AID588795
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.14620.000627.21521,122.0200AID651741; AID743202
gemininHomo sapiens (human)Potency14.80980.004611.374133.4983AID624296; AID624297
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency2.81840.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.01190.026622.448266.8242AID651802
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.60120.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)62.71100.10000.10000.1000AID652151
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)62.71100.10000.10000.1000AID652151
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Thymidine kinase, cytosolicHomo sapiens (human)Ki597.50000.09001.52137.0000AID210881; AID210882
Thymidine kinase, cytosolic Rattus norvegicus (Norway rat)Ki1,700.00002.40004.20006.5000AID210886
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)4.83000.00011.076810.0000AID289142; AID491848
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd44.00000.08933.31358.0000AID1238542
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.33330.00040.61539.7000AID199850; AID200001; AID200002
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)Km133.00000.29002.27675.0000AID1656988
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC90 (µMol)0.10000.00170.03850.3100AID198575
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (612)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID45855Cytotoxic concentration of compound required to reduce the viability of mock infected CEM cells by 50%2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.
AID388698Cytostatic activity against human wild type CEM/0 cellss2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates.
AID1611213Cytotoxicity against human MT4 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID104997Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID520604Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID548826Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID581049Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as depletion of mitochondrial DNA level at 1 uM by real-time PCR2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.
AID232738Selectivity index expressed as ratio of IC50 (CEM-C113) to EC50 from RT assay1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.
AID86851Concentration required to inhibit 50% of Hepatitis B virus replication2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID422692Ratio of IC50 for HIV1 with reverse transcriptase K70G/M184V mutation to IC50 for wild type HIV12007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID302621Cytotoxicity against human MT2 cells by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
From docking false-positive to active anti-HIV agent.
AID15559Distribution of compound in mice brain was measured after 6 hr1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.
AID681387TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID371702Cytostatic activity against wild type human CEM cells2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Doubly loaded cycloSaligenyl-pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates).
AID548827Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID584630Toxicity in human subcutaneous preadipocytes assessed as decrease of PPARgamma expression at 0.1 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID280848Chemical stability in phosphate buffer at pH 7.32007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID548803Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1611216Selectivity index, ratio of CC50 for human MT4 cells to IC50 for antiviral activity against HIV-2 ROD infected in human MT4 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID556526Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID280805Antiviral activity against H1V2 in CEM/0 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides.
AID1724846Substrate activity at human DNA polymerase beta incubated at 37 degC for 60 mins and at 80 degC for 7 mins by primer extension assay
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID306637Antiviral activity against HIV1 3B in MT2 cells assessed as inhibition of viral-mediated T-cell death by MTT method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
AID46815The cytotoxicity was measured on wild type CEM/O cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID259754Antiviral activity against wild-type HIV1 in MT2 cells by MTT assay2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID476473Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID1055515Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID105406Antiviral activity was measured on HIV-2 in MT-4 cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID698917Cytotoxicity against human CEM cells2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID25428Half life at pH 7.32003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID406053Oral bioavailability in human2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID32231Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 1000(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID20871Partition coefficient (P) in 1-octanol and 0.1 M Na3PO4 at pH 71990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1865841Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID246467Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID126594Competitive inhibition against rat mitochondrial thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID210886Competitive inhibition against rat cytoplasmic Thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID224944Compound was tested for anti-HIV activity in normal peripheral blood mononuclear cells by p24 production assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID698914Antiviral activity against HIV-2 infected in thymidine kinase deficient CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID47658Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.
AID739827Cytotoxicity against human MT2 cells after 5 days by MTT assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.
AID10494350% inhibition of MT-4 cell proliferation.2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
AID47149Effective concentration required to protect Human T-Lymphocyte (CEM) cells against cytopathogenicity of HIV-2 (ROD)2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID548815Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID46967Compound was evaluated for the cytotoxicity against CEM cell proliferation by 50%2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.
AID574195Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 2 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID406051Oral bioavailability in cynomolgus monkey2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID1655059Cytotoxicity against human CEM cells assessed as reduction in cell proliferation
AID1055510Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID26706Half-life period was measured in 30 mM sodium phosphate buffer at pH 7.3 at 37 degree C; not available1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID371700Antiviral activity against HIV2 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Doubly loaded cycloSaligenyl-pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates).
AID548841Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID581048Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as depletion of mitochondrial DNA level at 10 uM by real-time PCR2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.
AID125177In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1611220Antiviral activity against HIV-1 3IIB infected in thymidine kinase deficient human C8166 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID739828Antiviral activity against HIV-1 infected un MT2 cells assessed as virus-induced cytopathicity after 5 days by MTT assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.
AID47111In vitro inhibition of HIV-1 replication in human T-lymphocytic cells (CEM).1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.
AID373566Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 24 hrs post drug removal assessed as inhibition of viral replication at 1 to 6 uM measured 24 hrs postinfection by luciferase assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID47131Concentration required to protect CEM cells against cytopathicity of HIV-1 by 50%2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID406057Drug elimination in monkey urine after 30 days2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID584805Inhibition of electron transport protein complex 2/3 in human subcutaneous preadipocytes at 3 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1652585Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID26704Half-life period was measured in 30 mM sodium borate buffer at pH 8.9 at 37 degree C; not available1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID259755Cytotoxicity against MT2 cells2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID584815Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial membrane potential at 3 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID83414Concentration required to inhibit 50% of HIV-IIIB virus replication2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID1059727Cytotoxicity against human MT2 cells after 5 days by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.
AID548817Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID306638Cytotoxicity against human MT2 cells2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
AID302620Antiviral activity against HIV1 3B in human MT2 cells by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
From docking false-positive to active anti-HIV agent.
AID548825Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID46832In vitro effective compound concentration required to protect CEM/O cells against the cytopathogenicity of HIV-11999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.
AID246579Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID409411Cytotoxicity against human wild type CEM/0 cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
5-(1-Acetoxyvinyl)-cycloSaligenyl-2',3'-dideoxy-2',3'- didehydrothymidine monophosphates, a second type of new, enzymatically activated cycloSaligenyl pronucleotides.
AID47462In vitro antiviral test was performed on HIV(LAV strain) infected CEM cells1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
AID47148Effective concentration required to protect Human T-Lymphocyte (CEM) cells against cytopathogenicity of HIV-1 (IIIB)2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID548814Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1068975Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID15558Distribution of compound in mice brain was measured after 3 hr1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.
AID32233Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 200(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID210881Inhibitory affect against rabbit thymus thymidine kinase and represented as molt/4F kinase.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID491847Cytotoxicity against human MT2 cells after 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID388695Antiviral activity against HIV1 in human wild type CEM/0 cellss2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates.
AID373362Drug metabolism in human CEM cells assessed as radioactive zidovudine triphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID280849Hydrolysis half life in CEM cell extracts at pH 6.92007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID574197Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID25422Half life at pH 1.22003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.
AID548804Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46996Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID548840Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID698915Antiviral activity against HIV-2 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides.
AID537582Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.
AID548582Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID391220Cytotoxicity against human CEM cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters.
AID246506Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID289142Inhibition of HIV1 reverse transcriptase2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID289144Antiviral activity against HIV1 with reverse transcriptase 6TAM mutation assessed as reduction of potency relative to wild type2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID46654Compound was tested for anti-HIV-2 activity in CEM/0 cell line1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.
AID104245Cytotoxic concentration required to reduce the viability of mock-infected MT-2 cells by 50%2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine.
AID47294Compound was tested for anti-HIV activity in TK-deficient CEM cells by microculture tetrazolium assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID548572Antiviral activity against HIV1 isolate 057 expressing wild type reverse transcriptase gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1656987Cytotoxicity against human MT2 cells2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID280853Antiviral activity against HIV2 ROD in CEM/0 cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID199981Inhibition of HIV-1 reverse transcriptase; + = active1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
AID245969Cytotoxic concentration was measured in CEM wild-type/thymidine-kinase-deficient CEM Cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID1652588Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
AID548838Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID280804Antiviral activity against HIV1 in CEM/0 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides.
AID548573Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID199850Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by reverse transcriptase (RT) assay.1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.
AID548806Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID584608Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA copy number per cell at 3 uM after 60 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1865838Anti-HIV activity against HIV-1 infected in human MT4 cells assessed as inhibition of viral replication
AID584806Inhibition of electron transport protein complex 4 in human subcutaneous preadipocytes at 3 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID227258Ratio of CD50 to ID50 was determined2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
AID423158Antiviral activity against wild type HIV2 ROD produced from full length pROD9 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID397590Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID46651Activity against HIV-2 in CEM cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID15556Distribution of compound in mice brain was measured after 24 hr r1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.
AID280852Antiviral activity against HIV1 in CEM/0 cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID1055518Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID584804Inhibition of electron transport protein complex 1/3 in human subcutaneous preadipocytes at 3 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID537580Cytotoxicity against human CEM/0 cells2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.
AID548811Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID422693Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by antivirogram biological cutoffs assay relative to wild type HIV12007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID43989Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts; Not determined1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID46649Activity against HIV-1 in CEM cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID373366Drug metabolism in human CEM cells assessed as radioactive stavudine monophosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID43987Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.
AID105764Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID246391Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422695Ratio of IC50 for HIV1 with reverse transcriptase K70G mutation to IC50 for wild type HIV12007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID280806Antiviral activity against H1V2 in TK-deficient CEM cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides.
AID1055519Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID548574Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID563944Antiviral activity against HIV1 pNL4-3 harboring chimeric pTKD infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID233721Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 2000(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID289145Antiviral activity against HIV1 with reverse transcriptase K65R mutation assessed as reduction of potency relative to wild type2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID154961Antiviral activity against HIV I strain (LAV) in human peripheral blood mononuclear (PBM) cells; Range is 0.009 - 0.041989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID548802Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID200001In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID590321Antiviral activity against Human immunodeficiency virus 1 BAL by MAGI assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.
AID289141Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID26708Half-life period was measured in RPMI-1640 culture medium at 37 degree C with 10% heat-inactivated fetal calf serum..; not available1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID106921Concentration required to inhibit 50% of host cell replication in MT-2 cells used against HIV studies2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID280854Antiviral activity against HIV2 ROD in CEM/TK- cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID47113In vitro inhibition of HIV-2 replication in human T-lymphocytic cells (CEM).1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.
AID548798Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46847Activity against HIV-1 in CEM/TK cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1611212Antiviral activity against wild type HIV-1 3B infected in human MT4 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID105766Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID548828Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID574199Cytotoxicity against human skeletal muscle Myotube assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID584636Toxicity in human subcutaneous preadipocytes assessed as decrease of adiponectin expression at 3 uM after 30 days by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID584623Toxicity in fully differentiated human subcutaneous preadipocytes assessed as cell death at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1655058Antiviral activity against HIV2 ROD infected in thymidine kinase-deficient human CEM cells assessed as inhibition of virus-induced giant cell formation measured after 4 to 5 days by microscopic analysis
AID581054Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as increase in total deoxynucleotides content at 10 uM after 2 to 10 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.
AID233725Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 50(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID584808Inhibition of citrate synthase in human subcutaneous preadipocytes at 3 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1700728Antiviral activity against HIV2 ROD infected in human TK-deficient CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
γ-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals.
AID21064Partition coefficient was measured.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID548819Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID556527Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID563939Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID1055512Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID391217Antiviral activity against HIV1 in human CEM cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters.
AID574186Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 2 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID373364Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine diphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID200144Ratio for inhibition of HIV-1 RT to that of type and HIV-1 RT M184V mutant was determined2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID1655060Selectivity index, ratio of CC50 for human CEM cells to EC50 for HIV1 3B infected in human CEM/0 cells
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID422694Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by vircotype clinical cutoffs assay relative to wild type HIV12007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID47295Compound was tested for anti-HIV activity in TK-deficient CEM cells by p24 production assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID556524Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID23287Partition coefficient (logD7.0)1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID235811Selectivity by CC50 of CEM cells/EC50 of CEM cells against HIV-11999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.
AID574194Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 2 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID46652Compound was tested for anti-HIV-1 activity in CEM/0 cell line1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.
AID1237700Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.
AID581052Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as effect on total deoxynucleotides content at 1 uM after 2 to 10 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.
AID548824Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548834Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID15557Distribution of compound in mice brain was measured after 2 hr1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.
AID82564The 90% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
AID409409Antiviral activity against HIV2 replication in human wild type CEM/0 cells assessed as virus-induced cytopathic effect2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
5-(1-Acetoxyvinyl)-cycloSaligenyl-2',3'-dideoxy-2',3'- didehydrothymidine monophosphates, a second type of new, enzymatically activated cycloSaligenyl pronucleotides.
AID234204Therapeutic index (Ratio = ID50/ED50).1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID574200Cytotoxicity against human skeletal muscle Myoblast at 100 uL on day 5 by WST-1 assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID548576Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID574201Cytotoxicity against human skeletal muscle Myotube at 100 uL on day 5 by WST-1 assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID143439Antimycobacterial activity against Mycobacterium tuberculosis strain H37Rv2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.
AID24722Estimated half-life at 20 degree C in 0.05 M pH 2 NaH2PO4 buffer2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID32368Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 10(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID232739Selectivity index expressed as the ratio of CC50 to EC502004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.
AID328885Toxicity in human HeLa cells transfected with GFP-prelamin A construct assessed as accumulation of uncleaved protein at 20 uM by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID548808Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID260237Antiviral activity against HIV1 3B in MT2 cells by MTT assay2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID406052Oral bioavailability in mouse2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID47293Compound was tested for anti-HIV activity in TK-deficient CEM cells by inhibition of reverse transcriptase activity1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID1611215Antiviral activity against HIV-2 ROD infected in human MT4 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID1652587Antiviral activity against HIV2 ROD infected in human TK-deficient CEM/TK(-) cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID548820Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID563940Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID373363Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine monophosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID224941Compound was tested for anti-HIV activity in normal peripheral blood mononuclear cells by inhibition of reverse transcriptase activity1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID584620Toxicity in human subcutaneous preadipocytes assessed as decrease of cell cultures at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID84773Concentration required to inhibit 50% of HSV-2 replication; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID548579Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID154975Effective concentration required to inhibit P24 antigen production in PHA-PBM cells exposed to HIV-1 LAI2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID246644Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID590322Antiviral activity against Human immunodeficiency virus 1 3B infected in human SupT1 cells by cell-associated transmission assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.
AID548577Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID47001In vitro effective compound concentration required to protect CEM/TK cells against the cytopathogenicity of HIV-11999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.
AID235904Selectivity index expressed as ratio of IC50 (CEM-C113) to EC50 from MTT assay1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.
AID200002In vitro antiviral activity against HIV-1 Reverse transcriptase wild type2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID10624050% inhibition of HIV replication in MT-4 cells2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
AID405582Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID299251Inhibition of HIV1-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID1700727Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of virus-induced syncytia cell formation measured after 4 to 5 days by microscopic analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
γ-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID328883Toxicity in mouse fibroblast cells assessed as accumulation of prelamin A at 20 uM after 10 days by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID233715Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 100(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID235704Selectivity index of CD50 to ED50 of MT-4 cells1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID82562The 50% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
AID574187Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID373384Stability in human CEM cells assessed as intracellular radioactive triphosphate metabolite accumulation at 2 uM incubated for 24 hrs measured after 24 hrs of compound removal assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID373382Stability in human CEM cells assessed as total intracellular radioactive phosphorylated metabolite remaining at 2 uM incubated for 24 hrs measured after 24 hrs of compound removal assessed per 10'6 cells relative to 0 hrs after compound removal2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID306639Therapeutic index, ratio of IC50 for human MT2 cells to EC50 for HIV1 3B2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
AID590319Cytotoxicity against human HeLa P4/R5 cells by MTS assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.
AID299253Cytotoxicity against CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID698916Antiviral activity against HIV-1 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides.
AID548810Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID584632Toxicity in human subcutaneous preadipocytes assessed as decrease of C/EBPalpha expression at 0.1 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1724843Antiviral activity against HIV2 ROD infected in human TK-deficient CEM/TK- T-cells assessed as reduction in virus-induced cytopathogenicity by measuring syncytia cell formation incubated for 4 to 5 days by microscopy
AID1700726Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of virus-induced syncytia cell formation measured after 4 to 5 days by microscopic analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
γ-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548829Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID373361Drug metabolism in human CEM cells assessed as radioactive zidovudine diphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1237699Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.
AID563942Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID373383Stability in human CEM cells assessed as intracellular radioactive triphosphate metabolite remaining at 2 uM incubated for 24 hrs measured after 4 hrs of compound removal assessed per 10'6 cells relative to 0 hrs after compound removal2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID584604Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA abundance at 3 uM after 30 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID515928Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathic effect2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis and anti-HIV-1 evaluation of phosphonates which mimic the 5'-monophosphate of 4'-branched 2',3'-didehydro-2',3'-dideoxy nucleosides.
AID104310Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID373360Drug metabolism in human CEM cells assessed as radioactive zidovudine monophosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID289143Cytotoxicity against MT2 cells2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID10624190% inhibition of HIV replication in MT-4 cells2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
AID44136Minimal cytotoxic concentration required to cause morphological alteration of C3H/3T3 fibroblast culture cells; Not determined1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID1068980Antiviral activity against HIV-1 3B infected in human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID476469Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID198575Inhibitory activity against human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT)2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.
AID32239Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 50(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID409408Antiviral activity against HIV1 replication in human wild type CEM/0 cells assessed as virus-induced cytopathic effect2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
5-(1-Acetoxyvinyl)-cycloSaligenyl-2',3'-dideoxy-2',3'- didehydrothymidine monophosphates, a second type of new, enzymatically activated cycloSaligenyl pronucleotides.
AID548580Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID210882Inhibitory affect against rabbit thymus thymidine kinase1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID537584Antiviral activity against murine sarcoma virus infected in human C3H/3T3 cells assessed as inhibition of virus-induced cell transformation2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.
AID1611219Antiviral activity against wild type HIV-1 3B infected in wild type human C8166 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1611214Selectivity index, ratio of CC50 for human MT4 cells to IC50 for antiviral activity against HIV-1 IIIB infected in MT4 cells2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID1655056Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of virus-induced giant cell formation measured after 4 to 5 days by microscopic analysis
AID548571Antiviral activity against HIV1 isolate 056 expressing wild type reverse transcriptase gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID46803Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID1059728Antiviral activity against HIV1 3B infected in human MT2 cells after 5 days by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID537581Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.
AID548835Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID246558Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID105750Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID1611221Aqueous solubility of compound in phosphate buffered saline at pH 7.4 incubated for 2 hrs by turbidimetric analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID1865842Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability
AID548587Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID47114Antiviral activity evaluated as the ability to inhibit the replication of HIV-2 in human T-lymphocytic cells (CEM)1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID47640Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID1656988Substrate activity at human thymidine kinase 1 assessed as Km incubated for 24 hrs2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID1055516Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID46823Antiviral activity was measured on HIV-2 in wild-type CEM/O cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID105763Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration; Range is 10-401987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID548801Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548581Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID47132Concentration required to protect CEM cells against cytopathicity of HIV-2 by 50%2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.
AID1656986Antiviral activity against HIV1 3B infected in human MT2 cells2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID46819Antiviral activity was measured on HIV-1 in wild-type CEM/O cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID548575Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46640Cytotoxic concentration against CEM cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID85723Concentration required to inhibit 50% of HSV-1 replication; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID1652586Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID584631Toxicity in human subcutaneous preadipocytes assessed as decrease of PPARgamma expression at 3 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID8194In vitro hydrolysis in human plasma; no data2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.
AID126600Affinity towards mitochondrial thymidine kinase relative to TdR.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID548822Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548833Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID388697Antiviral activity against HIV2 in thymidine kinase deficient human CEM/TK- cellss2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates.
AID373392Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 2 uM after 24 hrs by luciferase assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID397589Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID581053Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as effect on total deoxynucleotides content at 10 uM after 2 to 10 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.
AID1724841Antiviral activity against HIV1 3B infected in human CEM/0 CD4+ T cells assessed as reduction in virus-induced cytopathogenicity by measuring syncytia cell formation incubated for 4 to 5 days by microscopy
AID391218Antiviral activity against HIV2 ROD in thymidine kinase deficient human CEM cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID246557Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID1724842Antiviral activity against HIV2 ROD infected in human CEM/0 CD4+ T cells assessed as reduction in virus-induced cytopathogenicity by measuring syncytia cell formation incubated for 4 to 5 days by microscopy
AID88973Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID275090Cytotoxicity against MAGI-CCR5 cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID423281Selectivity ratio of EC50 for multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase to EC50 for wild type HIV1 NL4-32008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID491848Inhibition of HIV1 reverse transcriptase-mediated thymidine incorporation into D23/D36 primer-template preincubated for 15 mins by polyacrylamide gel-electrophoresis2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.
AID574190Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCO3 mitochondrial RNA level on day 2 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID584633Toxicity in human subcutaneous preadipocytes assessed as decrease of C/EBPalpha expression at 3 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID548585Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID409410Antiviral activity against HIV2 replication in human thymidine kinase deficient CEM cells assessed as virus-induced cytopathic effect2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
5-(1-Acetoxyvinyl)-cycloSaligenyl-2',3'-dideoxy-2',3'- didehydrothymidine monophosphates, a second type of new, enzymatically activated cycloSaligenyl pronucleotides.
AID42386Protection of C8166 cells against the cytopathic effect of HIV isolate CBL-11989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.
AID548816Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID540235Phospholipidosis-negative literature compound
AID1865843Cytotoxicity against human MT4 cells assessed as reduction in cell viability
AID548807Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548830Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID105403Antiviral activity was measured on HIV-1 in MT-4 cells1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID1068978Cytotoxicity against human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID548812Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID584818Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial mass at 3 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1068976Cytotoxicity against human CEM/0 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID392536Antiviral activity against Vaccinia virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548584Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID373391Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 6 uM after 24 hrs by luciferase assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID563936Antiviral activity against wild-type HIV1 pNL4-3 infected in TZM-bl cells by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID46804Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID275065Antiviral activity against HIV1 in MAGI-CCR5 cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1865836Anti-HIV activity against HIV-1 infected in human CEM-SS cells assessed as inhibition of viral replication
AID491770Antiviral activity against HIV1 3B infected in human MT-2 cells assessed as inhibition of viral-mediated cell death after 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.
AID574198Cytotoxicity against human skeletal muscle Myotube assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID584619Toxicity in human subcutaneous preadipocytes assessed as triacylglyceride droplets at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID548800Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1895576Inhibition of DENV-2 RNA-dependent RNA polymerase in African green monkey Vero cells measured for 24 to 72 hrs relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 224Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors.
AID590320Antiviral activity against Human immunodeficiency virus 1 3B by MAGI assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.
AID373381Stability in human CEM cells assessed as intracellular radioactive phosphorylated metabolite accumulation at 2 uM incubated for 24 hrs measured after 8 hrs of compound removal assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1724847Substrate activity at human DNA polymerase alpha incubated at 37 degC for 60 mins and at 80 degC for 7 mins by primer extension assay
AID1237702Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.
AID46991Compound was tested for anti-HIV-2 activity in CEM/TK- cell line1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.
AID1724844Cytotoxicity in human CEM cells assessed as reduction in cell proliferation
AID42385Pprotection of C8166 cells against the cytopathic effect of HIV isolate RF1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.
AID1055513Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID1655057Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of virus-induced giant cell formation measured after 4 to 5 days by microscopic analysis
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID233146Differential affinity is the ratio between M-TK and C-TK1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID548586Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID373567Antiviral activity against 0.1 MOI HIV1 3B in 48 hrs pretreated human TZM-b1 cells infected 24 hrs post drug removal assessed as inhibition of viral replication at 1 to 6 uM measured 24 hrs postinfection by luciferase assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1055517Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID548805Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1865837Anti-HIV activity against HIV-1 infected in human CEM-TK(-) cells assessed as inhibition of viral replication
AID274989Cytotoxicity against MT4 cells MTT assay2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574189Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCYB mitochondrial RNA level on day 2 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID548836Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID82278Inhibitory activity against HIV-1 IIIB to achieve 50% protection of MT-2 cells2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine.
AID515929Cytotoxicity against human MT4 cells assessed as reduction of cell viability2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis and anti-HIV-1 evaluation of phosphonates which mimic the 5'-monophosphate of 4'-branched 2',3'-didehydro-2',3'-dideoxy nucleosides.
AID584621Toxicity in human subcutaneous preadipocytes assessed as decrease of cell viability measured every 5 days at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID19436Partition coefficient (logP)2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.
AID371699Antiviral activity against HIV1 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Doubly loaded cycloSaligenyl-pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates).
AID1238542Binding affinity to human serum albumin with excitation at 280 nm after 2 hrs by spectrofluorimetric analysis2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
AID1055520Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID388696Antiviral activity against HIV2 in human wild type CEM/0 cellss2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates.
AID46818The cytotoxicity was measured on wild type CEM/O cells.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID105131Activity against HIV-1 in MT-4 cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548809Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID280850Hydrolysis half life in RPMI-1650/FCS medium at pH 7.62007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID233719Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 200(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID548799Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID32235Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 2000(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID1700729Cytotoxicity against human CEM/0 CD4+ T cells assessed as reduction in cell viability2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
γ-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID105554Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID1068979Antiviral activity against HIV-2 ROD infected in human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID46975In vitro cytotoxic concentration in CEM cells.1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.
AID104763Cytotoxic concentration against MT-4 cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID584637Toxicity in human subcutaneous preadipocytes assessed as decrease of insulin-sensitizing adipokine expression at 3 uM after 30 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID328884Toxicity in mouse fibroblast cells assessed as accumulation of prelamin A at 40 uM after 10 days by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID373358Drug metabolism in human CEM cells assessed as radioactive stavudine diphosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID15555Distribution of compound in mice brain was measured after 1 hr1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.
AID82565The 90% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
AID476468Cytotoxicity against human MT2 cells by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID47150Effective concentration required to protect activity Human CEM/TK- cells against cytopathogenicity of HIV virus2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID233713Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 10(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID299252Inhibition of HIV2-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID423157Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID26702Half-life period was measured in 30 mM TRIS buffer at pH 6.9 at 37 degree C; not available1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID246466Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID233717Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 1000(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID233727Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 500(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID46851Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID572767Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID406050Oral bioavailability in rhesus monkey at 60 mg/kg2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID46999Concentration required to protect CEM/TK- cells against cytopathicity of HIV-2 by 50%2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.
AID224943Compound was tested for anti-HIV activity in normal peripheral blood mononuclear cells by microculture tetrazolium assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
AID25425Half life at pH 2.02003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.
AID520605Cytotoxicity against human WI38 cells by neutral red assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID46833In vitro effective compound concentration required to protect CEM/O cells against the cytopathogenicity of HIV-21999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.
AID563943Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID373368Drug metabolism in human CEM cells assessed as radioactive stavudine triphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID46814In vitro concentration required to inhibit HIV-2 infected CEM/O cell proliferation1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.
AID476472Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID235639Selectivity index by CC50 of CEM cells/EC50 of CEM cells against HIV-11999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID537583Antiviral activity against HIV2 ROD infected in human CEM/TK- cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.
AID548583Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID45845Compound was tested for cytostatic activity in CEM cell line1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.
AID373554Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication after 24 hrs by luciferase assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID423280Antiviral activity against multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID391219Antiviral activity against HIV2 ROD in human CEM cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters.
AID520606Selectivity index, ratio of CC50 for human WI38 cells to EC50 for BK polyomavirus ATCC VR8372008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID1237701Antiviral activity against HIV2 ROD infected in human thymidine kinase deficient CEM/TK- cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.
AID572768Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID373367Drug metabolism in human CEM cells assessed as radioactive stavudine diphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID548832Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548818Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1724848Substrate activity at human DNA polymerase gamma incubated at 37 degC for 60 mins and at 80 degC for 7 mins by primer extension assay
AID46976Cytotoxic concentration in Wild Type CEM cells1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID1055514Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID548821Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID373359Drug metabolism in human CEM cells assessed as radioactive stavudine triphosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID584807Inhibition of electron transport protein complex 5 in human subcutaneous preadipocytes at 3 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID548813Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID104416Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID104596The concentration required to cause a 50% inhibition of cell proliferation was determined in MT-4 cell culture.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.
AID274988Antiviral activity against HIV1 3B in MT4 cells by MTT assay2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines.
AID371701Antiviral activity against HIV2 in thymidine kinase deficient human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Doubly loaded cycloSaligenyl-pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates).
AID106768Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID105745Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.00032 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID574196Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID574193Cytotoxicity against human skeletal muscle Myotube assessed as decrease in MTCO3 mitochondrial RNA level on day 5 by RT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
AID584618Toxicity in human subcutaneous preadipocytes assessed as acquisition of adipocyte shape at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID556525Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID548831Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548578Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46974Cytostatic concentration required to inhibit Human T-Lymphocyte (CEM) cells proliferation caused by HIV-1 (IIIB)2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
AID548823Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID216007Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID392504Antiviral activity against Cowpox virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID26710Half-life period was measured in RPMI-1640 culture medium at 37 degree C without FCS.; not available1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.
AID1068977Antiviral activity against HIV-2 ROD infected in human CEM/0 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID280807Cytotoxicity against CEM/0 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides.
AID563941Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID234660Ratio CC50/EC50 for HIV-1 in CEM/0 cells1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID32066Required dose to reduce viability of normal uninfected ATH8 cells.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID476470Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID47623Cellular toxicity was measured in CEM cells after 8 days by using a [3H]- thymidine uptake assay1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
AID1055509Cytotoxicity against human CEM cells2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
AID406056Terminal phase half life in rhesus monkey2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID548839Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID47641Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID260238Cytotoxicity against human MT2 cells by MTT assay2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID373365Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine triphosphate accumulation at 2 uM assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID563938Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID32218Protection of ATH8 cells against the cytopathic effect of HIV isolate HTLF IIIB1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.
AID476471Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID104600The concentration required to cause a 50% inhibition of HIV reproduction was determined in MT-4 cell culture for free forms2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.
AID47657Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.
AID46850Cytostatic concentration required to inhibit CEM/0 cells proliferation by 50%1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
AID47112Antiviral activity evaluated as the ability to inhibit the replication of HIV-1 in human T-lymphocytic cells (CEM)1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.
AID584622Toxicity in human subcutaneous preadipocytes assessed as cell death at 3 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID105748Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.008 uM concentration; Range is 10-401987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID458192Activity at Drosophila melanogaster dNK by spectrophotometry2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.
AID373357Drug metabolism in human CEM cells assessed as radioactive stavudine monophosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID105132Activity against HIV-2 in MT-4 cells (in vitro)1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.
AID548588Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID210888Affinity towards cytoplasmic Thymidine kinase relative ot TdR.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID32229Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 100(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID104415Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID405412Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID422691Ratio of IC50 for HIV1 with reverse transcriptase K70E/M184V mutation to IC50 for wild type HIV12007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID584606Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA abundance at 3 uM after 60 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID563937Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
AID46176Effective concentration of compound achieving 50% protection in CEM cell lines against the cytopathic effect of HIV-12004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.
AID289146Antiviral activity against HIV with reverse transcriptase M184V mutation assessed as reduction of potency relative to wild type2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID572769Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID548837Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay relative to wild type2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID245944Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID152642Cytotoxic effect in uninfected human peripheral blood mononuclear (PBM) cells1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID246390Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID280851Hydrolysis half life in human serum at pH 6.82007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.
AID32241Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 500(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID32065Protection of ATH8 cells against the cytopathic effect of HIV.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,755)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (1.20)18.7374
1990's382 (21.77)18.2507
2000's909 (51.79)29.6817
2010's399 (22.74)24.3611
2020's44 (2.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.93 (24.57)
Research Supply Index7.72 (2.92)
Research Growth Index6.09 (4.65)
Search Engine Demand Index76.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials347 (18.27%)5.53%
Reviews104 (5.48%)6.00%
Case Studies161 (8.48%)4.05%
Observational8 (0.42%)0.25%
Other1,279 (67.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (131)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914]Phase 2171 participants (Actual)Interventional2008-03-31Completed
"Safeguard the Household - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country" [NCT00255840]812 participants (Actual)Interventional2006-07-31Completed
A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen [NCT00135369]Phase 3300 participants Interventional2002-09-30Completed
The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy [NCT00005918]Phase 3730 participants Interventional2000-06-30Completed
A Pilot Open Label, Multicenter Study to Evaluate the Role of Stavudine (d4T) in the Treatment of AIDS Dementia Complex [NCT00002246]Phase 320 participants Interventional1997-10-31Completed
Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen [NCT00002240]Phase 20 participants Interventional1999-03-31Completed
A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studie [NCT00116298]Phase 3900 participants Interventional2001-01-31Completed
Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in An [NCT00116116]Phase 470 participants Interventional2002-03-31Completed
Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily [NCT00002224]Phase 3120 participants Interventional1999-03-31Completed
A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months [NCT00312091]Phase 1/Phase 244 participants (Actual)Interventional2006-12-31Completed
A Randomized Double-Blind Study of Safety, Virologic and Immunological Effects of Stavudine Plus Lamivudine (3TC) Versus Zidovudine Plus Lamivudine in HIV-Infected Subjects Following At Least Six Months of Zidovudine Therapy [NCT00002371]Phase 380 participants Interventional1996-06-30Completed
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581]Phase 33,526 participants (Actual)Interventional2005-02-28Completed
[NCT00618176]Phase 4198 participants (Actual)Interventional2005-01-31Completed
Effect of Cytoreductive Chemotherapy Combined With Highly Active Antiretroviral Therapy on Lymph Node HIV DNA in HIV-Infected Subjects [NCT00000899]Phase 110 participants InterventionalCompleted
[NCT00669487]Phase 3150 participants (Actual)Interventional2008-04-30Completed
A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients [NCT00127972]Phase 4763 participants (Actual)Interventional2004-02-29Completed
A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Act [NCT00528957]Phase 397 participants (Actual)Interventional2006-12-28Completed
Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. [NCT00830856]54 participants (Actual)Interventional2006-10-31Completed
A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging [NCT00006144]Phase 290 participants Interventional2000-10-31Completed
A Prospective Randomized Open-Label Clinical Trial to Evaluate the Comparative Efficacy and Safety of a Potent Antiretroviral Treatment Regimen With or Without Hydroxyurea for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion [NCT00006339]Phase 20 participants (Actual)InterventionalWithdrawn
A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00006208]Phase 30 participants Interventional2000-08-31Active, not recruiting
A Study of the Combination of Indinavir, Ritonavir, Enteric-Coated ddI and d4T In Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Experienced Patients: An Open-Label Study Investigating Differences Between Women and Men [NCT00006397]Phase 3200 participants Interventional2000-08-31Active, not recruiting
Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection [NCT00000919]900 participants InterventionalCompleted
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells [NCT00000822]Phase 146 participants InterventionalCompleted
Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy [NCT00000831]Phase 2280 participants InterventionalCompleted
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [NCT00000870]Phase 2200 participants InterventionalCompleted
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects [NCT00000882]Phase 2300 participants InterventionalCompleted
An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV-Infected Pediatric Patients [NCT00017992]Phase 2100 participants InterventionalRecruiting
Treatment Options for Protease Inhibitor-exposed Children [NCT01146873]Phase 3300 participants (Actual)Interventional2010-07-31Completed
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection. [NCT00002349]40 participants Interventional1995-01-31Completed
Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the Safety and Antiviral Activity of a Protease-Containing Regimen (d4T/ddI/IDV/RTV) Versus a Protease-Sparing Regimen (d4T/ddI/EFV) and the Ability of Interleukin-2 to Purge HIV F [NCT00006154]Phase 3165 participants (Anticipated)InterventionalCompleted
The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients [NCT00006190]Phase 40 participants Interventional2000-11-30Completed
A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons [NCT00000922]1,710 participants InterventionalCompleted
A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion [NCT00000940]Phase 2121 participants (Actual)Interventional1999-05-31Completed
A Prospective Randomized Double-Blind Trial of Three Maintenance Regimens for HIV-Infected Subjects Receiving Induction Therapy With Zidovudine, Lamivudine and Indinavir [NCT00001084]Phase 2500 participants InterventionalCompleted
Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303 [NCT00001087]Phase 2300 participants InterventionalCompleted
A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection [NCT00000789]Phase 2230 participants InterventionalCompleted
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 [NCT00000891]Phase 234 participants InterventionalCompleted
Treatment Outcome of Children With HIV Infection [NCT00476606]1,000 participants (Anticipated)Observational2003-03-31Active, not recruiting
Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis [NCT01075152]Phase 4177 participants (Actual)Interventional2010-11-30Completed
A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Ef [NCT02670772]Phase 31,077 participants (Actual)Interventional2012-07-31Completed
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Stru [NCT00192660]Phase 480 participants (Actual)Interventional2003-02-28Completed
The Adult Antiretroviral Treatment and Resistance Study (Tshepo) [NCT00197613]Phase 3650 participants Interventional2002-12-31Completed
Trial of Stavudine (d4T) Plus Didanosine (ddI) in Children on Long-Term Stavudine Monotherapy, and Stavudine Versus Stavudine Plus Didanosine in Children on Long-Term Zidovudine Monotherapy: A Rollover Protocol for ACTG 240 Participants and Children Recei [NCT00000851]Phase 2198 participants InterventionalCompleted
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Rescriptor (Delavirdine Mesylate), and MKC-442 (With or Without Hy [NCT00002420]Phase 225 participants InterventionalTerminated
A Phase II, Randomized, Open-Label Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals With Virological Evidence of Nelfinavir Treatment Failure as Reflected by Plasma HIV RNA Concentration of >= 1,000 Copies/ml [NCT00000918]Phase 2300 participants InterventionalCompleted
A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI [NCT00000924]Phase 2120 participants InterventionalCompleted
A Phase II, Randomized, Open-Label Study of Maximally Assisted Therapy (MAT) Compared to Self-Administered Therapy (SAT) for the Treatment of HIV Infection in Antiretroviral Naive Subjects With CD4 Greater Than or Equal to 200 Cells/mm3 [NCT00001122]Phase 274 participants InterventionalCompleted
A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive [NCT00002412]Phase 20 participants InterventionalCompleted
A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Epivir 150 Mg BID Versus Epivir 300 Mg Once-Daily When Administered for 24 Weeks in Combination With FDA-Approved Dosage Regimens of Zerit and Either Crixivan or Viracept in Subjects W [NCT00002442]Phase 20 participants Interventional1999-06-30Completed
Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. [NCT00455585]Phase 418 participants Interventional2007-01-31Completed
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (R [NCT00002184]Phase 2120 participants InterventionalCompleted
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC [NCT00002208]Phase 3400 participants InterventionalCompleted
A Randomized Controlled Clinical Study to Determine If the Addition of HIV RNA Viral Load Is an Effective Tool in Determining Treatment Regimens for HIV-Infected Patients [NCT00002376]Phase 4540 participants InterventionalCompleted
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) f [NCT00002418]Phase 225 participants InterventionalTerminated
A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine [NCT00002424]Phase 2186 participants InterventionalSuspended
A Multicenter, Open-Label, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate/d4T/3TC Versus Indinavir Sulfate/Nelfinavir Mesylate/d4T/3TC in HIV-Infected Individuals [NCT00002430]220 participants InterventionalCompleted
Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients [NCT00004578]Phase 1/Phase 2100 participants (Actual)Interventional1997-11-30Completed
A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40mg BID) Plus Lamivudine (150mg BID) Plus Nelfinavir (1250mg BID) Versus Abacavir (300mg BID) Plus Combivir (3TC 150 [NCT00005106]Phase 4230 participants Interventional1999-09-30Completed
Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Thera [NCT02249130]Phase 218 participants (Actual)Interventional1999-03-31Completed
Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY [NCT00235222]Phase 457 participants Interventional2004-06-30Active, not recruiting
Safeguard the Household: A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country [NCT00080522]813 participants Interventional2005-02-28Completed
A Randomized Clinical Trial Assessing Continuous HAART Versus Interrupted HAART in a Resource Poor Clinic [NCT00100646]30 participants (Actual)Interventional2007-03-31Completed
A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral T [NCT00002308]0 participants InterventionalCompleted
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs [NCT00001083]Phase 2240 participants InterventionalCompleted
A Randomized Controlled Trial to Compare the Efficacy of a Four Drug Antiretroviral Regimen Alone or in Combination With GM-CSF or IL-12 Administered to HIV-1 Infected Subjects as Measured by the Characteristics of Viral Decay [NCT00000896]24 participants InterventionalCompleted
One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T) [NCT00002354]540 participants InterventionalCompleted
Evaluating Responses to Antiretroviral Drugs in Cells and Tissues (The ERADICATE Study): Comprehensive Comparisons of Viral and Cellular Dynamics Among Previously-Untreated Subjects With Acute HIV Infection (Seroconversion Syndrome) or Recently Acquired H [NCT00006443]24 participants InterventionalCompleted
A Pilot Open-Label Phase II Clinical Trial to Evaluate the Safety and Efficacy of a Compact Three Drug Antiretroviral Treatment Regimen for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion [NCT00007202]Phase 255 participants (Actual)InterventionalCompleted
A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex [NCT00000686]Phase 135 participants InterventionalTerminated
A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regi [NCT00014937]240 participants InterventionalCompleted
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine [NCT00001688]Phase 225 participants Interventional1998-01-31Completed
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy [NCT00055120]Phase 4283 participants (Actual)Interventional2003-03-31Completed
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection [NCT00013520]Phase 31,125 participants InterventionalCompleted
Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375 [NCT00034086]22 participants InterventionalCompleted
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection [NCT00050895]Phase 3775 participants InterventionalCompleted
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation [NCT00036452]Phase 2402 participants (Actual)InterventionalCompleted
A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavir [NCT00158821]Phase 3180 participants (Anticipated)Interventional2000-03-31Completed
Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL [NCT00342355]Phase 41,771 participants (Actual)Interventional2004-01-31Completed
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT) [NCT00427297]Phase 334 participants (Actual)Interventional2007-09-30Terminated(stopped due to There is no longer equipoise. DSMB recommended termination.)
Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients [NCT01601899]Phase 460 participants (Actual)Interventional2008-10-31Terminated(stopped due to DSMB decision to begin closeout process in view of April 2010 SA HAART guideline)
A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects [NCT00002411]0 participants Interventional1998-03-31Completed
A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 [NCT00000885]Phase 2440 participants InterventionalCompleted
Phase II Randomized, Open-Label Study of Maintenance of HIV RNA Suppression After Switching to ddI/d4T/HU vs. ddI/d4T/EFV vs. Continuing the Pre-Entry Protease Inhibitor Regimen [NCT00000939]Phase 2150 participants InterventionalCompleted
A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprena [NCT00001095]Phase 294 participants InterventionalCompleted
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy [NCT00002109]Phase 30 participants InterventionalCompleted
A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between 50 and 500 Cells/mm3 [NCT00002307]0 participants InterventionalCompleted
A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Ce [NCT00002379]Phase 2100 participants InterventionalCompleted
An Exploratory Study of Fortovase (Saquinavir) Soft Gelatin Capsules (SGC) Plus d4T and 3TC or Fortovase (Saquinavir) SGC Plus Nelfinavir and d4T in Patients With HIV-1 Associated Nephropathy [NCT00002397]Phase 324 participants InterventionalCompleted
An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals [NCT00002211]160 participants InterventionalCompleted
A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination With ddI and d4T in Subjects With HIV Infection [NCT00002427]Phase 1225 participants Interventional1999-05-31Completed
A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients [NCT00002451]Phase 28 participants InterventionalActive, not recruiting
A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals [NCT00002241]Phase 280 participants InterventionalActive, not recruiting
Long Term Follow-up of Patients Experiencing Structured Treatment Interruption (STI) With or Without Low Doses of Interleukin-2 During Primary HIV Infection (PHI) [NCT02300623]Phase 412 participants (Actual)Interventional2000-03-31Completed
A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 [NCT00000838]Phase 2256 participants InterventionalCompleted
A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma [NCT00000916]Phase 2399 participants InterventionalCompleted
A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex [NCT00000988]Phase 140 participants InterventionalCompleted
Multi-Drug Antiretroviral Therapy for Heavily Pretreated Pediatric AIDS Patients: A Phase I Proof of Concept Trial [NCT00001108]Phase 16 participants InterventionalCompleted
A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) [NCT00380770]Phase 4112 participants (Actual)Interventional2003-01-31Completed
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection [NCT00002176]0 participants Interventional1997-05-31Completed
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00002362]Phase 30 participants Interventional1999-08-31Suspended
A Phase IIIB Open-Label Trial Replacing Saquinavir HGC (Ro 31-8959) With Saquinavir SGC (Ro 31-8959) in Combination With Other Antiretroviral Drugs in Patients With HIV-1 Infection [NCT00002374]Phase 3120 participants InterventionalCompleted
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients [NCT00002230]Phase 3100 participants InterventionalCompleted
A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A o [NCT00002386]Phase 455 participants InterventionalCompleted
Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children [NCT00000872]Phase 255 participants (Anticipated)InterventionalCompleted
A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Infected Pregnant Women and Their Infants [NCT00000878]Phase 126 participants InterventionalCompleted
RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience [NCT00000902]Phase 1217 participants InterventionalCompleted
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs [NCT00002162]Phase 2140 participants InterventionalCompleted
An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of > [NCT00002168]200 participants InterventionalCompleted
A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) B [NCT00002378]Phase 3825 participants InterventionalCompleted
A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience [NCT00000841]Phase 31,750 participants InterventionalCompleted
A Phase I Safety and Pharmacokinetic Study of 1592U89 Alone and In Combination With Other Antiretroviral Agents in Infants and Children With HIV Infection [NCT00000865]Phase 132 participants InterventionalCompleted
A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection [NCT00000901]Phase 124 participants InterventionalCompleted
A Phase II Randomized Study of the Virologic and Immunologic Effects of d4T vs Zidovudine Plus d4T vs Zidovudine Plus Ddl in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and Greater Than 12 Weeks Zidovudine Experience [NCT00001063]Phase 2200 participants InterventionalCompleted
A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3 [NCT00002407]0 participants InterventionalCompleted
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients [NCT00002227]Phase 260 participants InterventionalCompleted
A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients [NCT00005000]Phase 4200 participants Interventional1999-12-31Active, not recruiting
Viral and Immune Dynamics in HIV-Infected Patients With Tuberculosis [NCT00004736]Phase 144 participants InterventionalCompleted
A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/ [NCT00004855]55 participants InterventionalCompleted
A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infe [NCT00005017]Phase 4300 participants InterventionalActive, not recruiting
Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART) [NCT00000923]110 participants InterventionalCompleted
A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience [NCT00001067]Phase 2105 participants InterventionalCompleted
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh [NCT00001091]Phase 1200 participants InterventionalCompleted
An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700 Cells/mm3 and HIV RNA Baseline Copy Numb [NCT00002369]200 participants InterventionalCompleted
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit) [NCT00002381]Phase 124 participants InterventionalCompleted
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection [NCT00002177]0 participants Interventional1997-05-31Completed
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients [NCT00002225]Phase 260 participants InterventionalCompleted
Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults [NCT01025830]Phase 420 participants (Actual)Interventional2006-02-28Completed
A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral Naive HIV-Infected Subjects [NCT00004583]Phase 3660 participants Interventional1999-03-31Completed
Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen [NCT00002429]Phase 3500 participants Interventional1999-07-31Completed
A Randomized, Double-Blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination With Twice-Daily Dosing of Stavudine in HIV-Infected Subjects [NCT00002207]0 participants Interventional2004-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00074581 (2) [back to overview]All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00074581 (2) [back to overview]Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00255840 (1) [back to overview]Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).
NCT00342355 (2) [back to overview]Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.
NCT00342355 (2) [back to overview]Serious Adverse Events
NCT00427297 (4) [back to overview]Immunologic Failure
NCT00427297 (4) [back to overview]Incidence of Mortality
NCT00427297 (4) [back to overview]Incidence of Severe Adverse Events (Excluding Mortality)
NCT00427297 (4) [back to overview]Viral Failure
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 144 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 192 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 240 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 288 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 336 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 384 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 432 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 48 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 480 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 528 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Percentage at 96 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks
NCT00528957 (46) [back to overview]Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks
NCT00528957 (46) [back to overview]Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)
NCT00528957 (46) [back to overview]Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks
NCT00528957 (46) [back to overview]Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks
NCT01025830 (2) [back to overview]Maximum Plasma Concentration of Drug
NCT01025830 (2) [back to overview]Area Under the Concentration-Time Curve(AUC)
NCT01075152 (10) [back to overview]Antiretroviral Therapy Tolerability
NCT01075152 (10) [back to overview]HIV-1 Viral Suppression
NCT01075152 (10) [back to overview]Incidence of Cryptococcal-relapse
NCT01075152 (10) [back to overview]Incidence of Immune Reconstitution Inflammatory Syndrome
NCT01075152 (10) [back to overview]Mortality
NCT01075152 (10) [back to overview]Safety of ART Initiation
NCT01075152 (10) [back to overview]Karnofsky Functional Status
NCT01075152 (10) [back to overview]Microbiologic Clearance
NCT01075152 (10) [back to overview]Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26
NCT01075152 (10) [back to overview]46-week Survival
NCT01146873 (5) [back to overview]CD4 Cell Percentage at 48 Weeks After Randomization
NCT01146873 (5) [back to overview]Viral Failure
NCT01146873 (5) [back to overview]Viral Rebound
NCT01146873 (5) [back to overview]Highest Grade ALT After Randomization
NCT01146873 (5) [back to overview]Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization

All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

All Incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. (NCT00074581)
Timeframe: Throughout study

Interventionevent rate per 100 person-yr (Number)
Early-ART0.44
Delayed-ART1.41

[back to top]

Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. Only acquisition from the index partner were included in the primary analysis, therefore, each endpoint was required to be confirmed (by genotyping) such that the viral envelop sequence in the index case matched that of the partner. (NCT00074581)
Timeframe: Throughout study

Interventionevent rate per 100 person-yr (Number)
Early-ART0.07
Delayed-ART1.03

[back to top]

Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).

Cumulative treatment failure is a composite endpoint made up of death, virological failure, toxicity failure and protocol-defined loss to follow-up failure. (NCT00255840)
Timeframe: 96 weeks

InterventionPercentage of participants (Number)
Antiretroviral Therapy Monitored by Medical Officer44
Antiretroviral Therapy Managed by Primary Health Care Nurse48

[back to top]

Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.

Progression of disease, AIDS, or death in treatment naive patients with advanced HIV diagnosis will be evaluated in the four randomly assigned regimens. (NCT00342355)
Timeframe: January 2004 until March 31 2008

Interventionparticipants (Number)
AZT+ddI+EFV93
AZT + ddI + r/LPV77
d4T + 3TC + EFV70
d4T + 3TC + r/LPV80

[back to top]

Serious Adverse Events

Safety outcomes in four different randomly assigned regimens (NCT00342355)
Timeframe: January 2004 until March 31, 2008

Interventionparticipant (Number)
AZT+ddI+EFV73
AZT + ddI + r/LPV69
d4T + 3TC + EFV64
d4T + 3TC + r/LPV60

[back to top]

Immunologic Failure

Immunologic treatment failure was defined as CD4% dropping below 15%, after a previous result greater than or equal to 15% (following along WHO Guidelines). (NCT00427297)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
NVP-containing2
NVP-sparing1

[back to top]

Incidence of Mortality

Death during follow-up (NCT00427297)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
NVP-containing4
NVP-sparing5

[back to top]

Incidence of Severe Adverse Events (Excluding Mortality)

(NCT00427297)
Timeframe: 2 years

Interventionevent (Number)
NVP-containing21
NVP-sparing6

[back to top]

Viral Failure

Virologic treatment failure was defined as follow-up (at least 24 weeks after enrollment date) viral load > 400 copies. (NCT00427297)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
NVP-containing2
NVP-sparing2

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks

This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 432 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-795
(Stavudine or Zidovudine)/TDF-302
All TDF-631

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks

This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: Baseline and 48 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-97
Stavudine or Zidovudine-11
All TDF2

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks

This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 480 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-923
(Stavudine or Zidovudine)/TDF-448
All TDF-813

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks

This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 528 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-710
All TDF-710

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks

This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 96 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-77
(Stavudine or Zidovudine)/TDF-56
All TDF-67

[back to top]

Change From Baseline in CD4 Percentage at 144 Weeks

This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 144 weeks

Interventionpercentage (Mean)
Tenofovir DF0.8
(Stavudine or Zidovudine)/TDF-0.1
All TDF0.3

[back to top]

Change From Baseline in CD4 Percentage at 192 Weeks

This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 192 weeks

Interventionpercentage (Mean)
Tenofovir DF1.1
(Stavudine or Zidovudine)/TDF0.6
All TDF0.8

[back to top]

Change From Baseline in CD4 Percentage at 240 Weeks

This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 240 weeks

Interventionpercentage (Mean)
Tenofovir DF1.3
(Stavudine or Zidovudine)/TDF-0.9
All TDF0.1

[back to top]

Change From Baseline in CD4 Percentage at 288 Weeks

This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 288 weeks

Interventionpercentage (Mean)
Tenofovir DF2.0
(Stavudine or Zidovudine)/TDF0.5
All TDF1.3

[back to top]

Change From Baseline in CD4 Percentage at 336 Weeks

This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 336 weeks

Interventionpercentage (Mean)
Tenofovir DF2.0
(Stavudine or Zidovudine)/TDF0.8
All TDF1.4

[back to top]

Change From Baseline in CD4 Percentage at 384 Weeks

This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 384 weeks

Interventionpercentage (Mean)
Tenofovir DF0.5
(Stavudine or Zidovudine)/TDF1.6
All TDF0.9

[back to top]

Change From Baseline in CD4 Percentage at 432 Weeks

This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 432 weeks

Interventionpercentage (Mean)
Tenofovir DF0.3
(Stavudine or Zidovudine)/TDF2.9
All TDF1.1

[back to top]

Change From Baseline in CD4 Percentage at 48 Weeks

This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: Baseline and 48 weeks

Interventionpercentage (Mean)
Tenofovir DF0.3
Stavudine or Zidovudine1.1
All TDF0.6

[back to top]

Change From Baseline in CD4 Percentage at 480 Weeks

This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 480 weeks

Interventionpercentage (Mean)
Tenofovir DF2.3
(Stavudine or Zidovudine)/TDF5.0
All TDF2.9

[back to top]

Change From Baseline in CD4 Percentage at 528 Weeks

This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 528 weeks

Interventionpercentage (Mean)
Tenofovir DF4.5
All TDF4.5

[back to top]

Change From Baseline in CD4 Percentage at 96 Weeks

This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 96 weeks

Interventionpercentage (Mean)
Tenofovir DF1.3
(Stavudine or Zidovudine)/TDF-0.1
All TDF0.6

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: 192 weeks

Interventionpercentage of participants (Number)
Tenofovir DF70.6
(Stavudine or Zidovudine)/TDF82.5
All TDF77.0

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: 240 weeks

Interventionpercentage of participants (Number)
Tenofovir DF70.6
(Stavudine or Zidovudine)/TDF75.7
All TDF73.2

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: 288 weeks

Interventionpercentage of participants (Number)
Tenofovir DF81.5
(Stavudine or Zidovudine)/TDF67.6
All TDF73.4

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: 336 weeks

Interventionpercentage of participants (Number)
Tenofovir DF90.9
(Stavudine or Zidovudine)/TDF100.0
All TDF95.3

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: 384 weeks

Interventionpercentage of participants (Number)
Tenofovir DF100.0
(Stavudine or Zidovudine)/TDF100.0
All TDF100.0

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: 432 weeks

Interventionpercentage of participants (Number)
Tenofovir DF100.0
(Stavudine or Zidovudine)/TDF85.7
All TDF95.0

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: 480 weeks

Interventionpercentage of participants (Number)
Tenofovir DF88.9
(Stavudine or Zidovudine)/TDF100.0
All TDF90.9

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: 528 weeks

Interventionpercentage of participants (Number)
Tenofovir DF100.0
All TDF100.0

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: 144 weeks

Interventionpercentage of participants (Number)
Tenofovir DF73.7
(Stavudine or Zidovudine)/TDF87.5
All TDF80.8

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF83.3
Stavudine or Zidovudine91.8
All TDF85.4

[back to top]

Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96

This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: 96 weeks

Interventionpercentage of participants (Number)
Tenofovir DF81.6
(Stavudine or Zidovudine)/TDF85.4
All TDF83.5

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: 144 weeks

Interventionpercentage of participants (Number)
Tenofovir DF63.2
(Stavudine or Zidovudine)/TDF75.0
All TDF69.2

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: 192 weeks

Interventionpercentage of participants (Number)
Tenofovir DF67.6
(Stavudine or Zidovudine)/TDF75.0
All TDF71.6

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: 240 weeks

Interventionpercentage of participants (Number)
Tenofovir DF70.6
(Stavudine or Zidovudine)/TDF73.0
All TDF71.8

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: 288 weeks

Interventionpercentage of participants (Number)
Tenofovir DF81.5
(Stavudine or Zidovudine)/TDF62.2
All TDF70.3

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: 336 weeks

Interventionpercentage of participants (Number)
Tenofovir DF86.4
(Stavudine or Zidovudine)/TDF90.5
All TDF88.4

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: 384 weeks

Interventionpercentage of participants (Number)
Tenofovir DF88.2
(Stavudine or Zidovudine)/TDF100.0
All TDF92.3

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: 432 weeks

Interventionpercentage of participants (Number)
Tenofovir DF100.0
(Stavudine or Zidovudine)/TDF71.4
All TDF90.0

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF70.8
Stavudine or Zidovudine85.7
All TDF68.5

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: 480 weeks

Interventionpercentage of participants (Number)
Tenofovir DF77.8
(Stavudine or Zidovudine)/TDF50.0
All TDF72.7

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: 528 weeks

Interventionpercentage of participants (Number)
Tenofovir DF100.0
All TDF100.0

[back to top]

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks

This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: 96 weeks

Interventionpercentage of participants (Number)
Tenofovir DF76.3
(Stavudine or Zidovudine)/TDF68.3
All TDF72.2

[back to top]

Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)

This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA < 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT00528957)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF88.6
Stavudine or Zidovudine89.6

[back to top]

Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)

This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT00528957)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF75.0
Stavudine or Zidovudine81.3

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks

This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 144 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-139
(Stavudine or Zidovudine)/TDF-146
All TDF-142

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks

This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 192 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-304
(Stavudine or Zidovudine)/TDF-177
All TDF-233

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks

This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 240 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-369
(Stavudine or Zidovudine)/TDF-296
All TDF-329

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks

This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 288 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-346
(Stavudine or Zidovudine)/TDF-256
All TDF-302

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks

This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 336 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-415
(Stavudine or Zidovudine)/TDF-283
All TDF-350

[back to top]

Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks

This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 384 weeks

Interventioncells/mm^3 (Mean)
Tenofovir DF-620
(Stavudine or Zidovudine)/TDF-305
All TDF-512

[back to top]

Maximum Plasma Concentration of Drug

Maximum concentration of drug in plasma that was attained post dosing (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing

Interventionmilligram/liter (Geometric Mean)
Generic Stavudine1.6
Brand Stavudine1.3
Generic Nevirapine8.8
Brand Nevirapine8.4
Generic Lamivudine1.0
Brand Lamivudine1.3

[back to top]

Area Under the Concentration-Time Curve(AUC)

Mean Area Under the Plasma Concentration-Time Curve for each drug, log transformed (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing

Interventionhour*milligram/liter (Geometric Mean)
Generic Stavudine3.6
Brand Stavudine3.4
Generic Nevirapine85.8
Brand Nevirapine79.2
Generic Lamivudine5.2
Brand Lamivudine6.4

[back to top]

Antiretroviral Therapy Tolerability

Incidence of antiretroviral therapy interruption by >=3 consecutive days (NCT01075152)
Timeframe: 26 weeks

Interventionparticipants (Number)
Earlier HIV Therapy5
Deferred HIV Therapy1

[back to top]

HIV-1 Viral Suppression

HIV-1 virologic suppression to <400 copies/mL at 26-weeks after enrollment (NCT01075152)
Timeframe: 26 weeks

Interventionparticipants (Number)
Earlier HIV Therapy43
Deferred HIV Therapy49

[back to top]

Incidence of Cryptococcal-relapse

Incidence of culture positive cryptococcal meningitis relapse (NCT01075152)
Timeframe: 46 weeks

Interventionparticipants (Number)
Earlier HIV Therapy2
Deferred HIV Therapy8

[back to top]

Incidence of Immune Reconstitution Inflammatory Syndrome

Incidence of cryptococcal-related immune reconstitution inflammatory syndrome through 46 weeks after enrollment. (NCT01075152)
Timeframe: 46 weeks

Interventionparticipants (Number)
Earlier HIV Therapy17
Deferred HIV Therapy9

[back to top]

Mortality

Intention to treat analysis of 26 week survival of all subjects enrolled. Reported below are the numbers of participants who died by Week 26. (NCT01075152)
Timeframe: 26 weeks from study entry

Interventionparticipants (Number)
Earlier HIV Therapy40
Deferred HIV Therapy27

[back to top]

Safety of ART Initiation

Incidence of Adverse Events (Grade 3,4,5) through 46-weeks, as defined by the National Institute of Allergy and Infectious Diseases, Division of AIDS toxicity classification scale, version 2009. (NCT01075152)
Timeframe: 46 weeks

Interventionparticipants (Number)
Earlier HIV Therapy73
Deferred HIV Therapy75

[back to top]

Karnofsky Functional Status

"Functional status via Karnofsky performance status score at 4, 26, 46 weeks.~Karnofsky Scale:~100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.~50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.~20 - Very sick; hospital admission necessary; active supportive treatment necessary.~10 - Moribund; fatal processes progressing rapidly. 0 - Dead" (NCT01075152)
Timeframe: 46 weeks

,
InterventionScores on a scale (Mean)
4 weeks26 weeks46 weeks
Deferred HIV Therapy709395
Earlier HIV Therapy709392

[back to top]

Microbiologic Clearance

Microbiologic clearance of cryptococcus as measured by serial quantitative cryptococcal cultures collected at diagnosis through 14 days of amphotericin therapy. The early fungicidal activity (EFA) of the rate of clearance is expressed as log10 colony forming units (CFU) of Cryptococcus neoformans per mL of CSF per day. (NCT01075152)
Timeframe: 4 weeks

,
Interventionlog10 CFU/mL/day (Mean)
EFA by mixed effects modelEFA by linear regression
Deferred HIV Therapy-0.31-0.35
Earlier HIV Therapy-0.31-0.39

[back to top]

Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26

Percentage of Participants who died by week 26 based on CSF white blood cell (WBC) count at study entry (time of randomization at a median of 8 days of anti-fungal therapy). (NCT01075152)
Timeframe: 26 weeks

,
Interventionpercentage of participants (Number)
CSF WBC <5 /mcl (n=33, 31)CSF WBC >5/mcL (n=42, 40)
Deferred HIV Therapy16.145
Earlier HIV Therapy48.540.5

[back to top]

46-week Survival

46-week survival by time-to-event analysis of all subjects enrolled (NCT01075152)
Timeframe: 46 weeks

Interventionparticipants (Number)
Earlier HIV Therapy41
Deferred HIV Therapy29

[back to top]

CD4 Cell Percentage at 48 Weeks After Randomization

CD4 Cell Percentage at 48 Weeks After Randomization (NCT01146873)
Timeframe: 48 weeks

Interventionpercentage of cells (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)34.7
Group 2: Efavirenz (EFV)37.5

[back to top]

Viral Failure

Probability of viral failure defined as >= 2 HIV RNA measurements >1000 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks

Interventionprobability of viral failure (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)0.020
Group 2: Efavirenz (EFV)0.027

[back to top]

Viral Rebound

Probability of viral rebound defined as >=1 HIV RNA measurements >50 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks

Interventionprobability of viral rebound (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)0.284
Group 2: Efavirenz (EFV)0.176

[back to top]

Highest Grade ALT After Randomization

Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening). (NCT01146873)
Timeframe: through 48 weeks post randomization

,
Interventionnumber of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4
Group 1: Lopinavir/Ritonavir (LPV/r)1398010
Group 2: Efavirenz (EFV)120161031

[back to top]

Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization

Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization (NCT01146873)
Timeframe: 40 weeks

,
Interventionpercentage of participants (Number)
Elevated total cholesterolElevated LDLAbnormal HDLAbnormal triglycerides
Group 1: Lopinavir/Ritonavir (LPV/r)24.818.64.822.8
Group 2: Efavirenz (EFV)13.39.84.210.5

[back to top]